Aytu BioPharma (AYTU) 10-Q/A21 Feb 232023 Q1 Quarterly report (amended)Financial data

Company Profile

Document and Entity Information

Document and Entity Information - $ / shares	3 Months Ended
Document and Entity Information - $ / shares	Sep. 30, 2022	Nov. 09, 2022
Cover [Abstract]
Entity Central Index Key	0001385818
Document Type	10-Q/A
Document Quarterly Report	true
Document Period End Date	Sep. 30, 2022
Document Transition Report	false
Entity File Number	001-38247
Entity Registrant Name	AYTU BIOPHARMA, INC.
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	47-0883144
Entity Address, Address Line One	373 Inverness Parkway
Entity Address, Address Line Two	Suite 206
Entity Address, City or Town	Englewood
Entity Address, State or Province	CO
Entity Address, Postal Zip Code	80112
City Area Code	720
Local Phone Number	437-6580
Title of 12(b) Security	Common Stock, par value $0.0001 per share
Entity Listing, Par Value Per Share	$ 0.0001
Trading Symbol	AYTU
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		3,121,471
Current Fiscal Year End Date	--06-30
Document Fiscal Year Focus	2023
Document Fiscal Period Focus	Q1
Amendment Flag	true
Amendment Description	Aytu BioPharam, Inc. ("Aytu", "Company", "we", "us", "our") is filing this Amendment No. 1 (this "Amendment") to its Quarterly Report on Form 10-Q for the quarter ended September 30, 2022 (the "Original Filing"), originally filed on November 14, 2022. With the exception of adjusting the shares to represent the reverse stock split on January 6, 2023 (as described below), this Amendment is presented as of the filing date of the Original Filing and does not reflect events occurring after that date, or modify or update disclosures in any way other than as required to reflect the restatements as described below. Accordingly, this Amendment should be read in conjunction with our filings with the U.S. Securities and Exchange Commission ("SEC") subsequent to the date on which we filed the Original Filing. This Amendment to the Original Filing amends our classification of certain warrants that were previously recorded as equity. These warrants according to generally accepted accounting principles in the United States ("GAAP") should have been classified as derivative warrant liabilities at fair value and marked to market at each reporting period, with changes in fair value recorded in earnings. The affected filing periods are the quarterly unaudited financial statements as of March 31, 2022 and September 30, 2022, and the audited financial statements as of June 30, 2022. SEC Staff Accounting Bulletin No. 99, "Materiality," and FASB, Statement of Financial Accounting Concepts No. 2 "Qualitative Characteristics of Accounting Information" indicate that quantifying and aggregating errors is only the beginning of an analysis of materiality and that both quantitative and qualitative factors must be considered in determining whether individual errors are material. The Company evaluated the errors and has determined that the impact was not material for the periods ended March 31, 2022 and June 30, 2022, but was material for the period ended September 30, 2022. The assessment resulted in a restatement of the previously issued financial statements reported in the Original Filing. The balance sheet as at June 30, 2022 included in this Amendment has also been adjusted for the correction of this immaterial error. Financial statements for period ended March 31, 2022 and year ended June 30, 2022 will be adjusted at the time of their reissuance. This Amendment includes the accounting impact in the periods as of and for the three months ended September 30, 2022, and as of June 30, 2022. The change in accounting for the warrants did not have any impact on our liquidity, cash flows, revenues or costs of operating in the affected periods. On January 6, 2023, the Company effected a reverse stock split in which each common stockholder received one share of common stock for every twenty shares held ("Reverse Stock Split"). All share and per share amounts in this Amendment have been adjusted to reflect the effect of the Reverse Stock Split. We are filing this Amendment to amend and restate the Original Filing with modification as necessary to reflect the restatement. The following items have been amended to reflect the restatement: Part I, Item 1. Consolidated Financial Statements Part I, Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations Part I, Item 4. Controls and Procedures Part II, Item 1A. Risk Factors Part II, Item 6. Exhibits Refer to Note 2 - Previously Reported Financial Statements to the condensed consolidated financial statements included in this Amendment for additional information and for the summary of the accounting impacts of these adjustments to the Company's financial statements as of and for the period ended September 30, 2022, and as of June 30, 2022.

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Sep. 30, 2022	Jun. 30, 2022
Current assets
Cash and cash equivalents	$ 23,811	$ 19,360
Accounts receivable, net	27,924	21,712
Inventory, net	12,871	10,849
Prepaid expenses	9,024	7,375
Other current assets	785	633
Total current assets	74,415	59,929
Property and equipment, net	2,672	3,025
Operating lease right-of-use asset	2,976	3,271
Intangible assets, net	69,108	70,632
Other non-current assets	829	766
Total non-current assets	75,585	77,694
Total assets	150,000	137,623
Current liabilities
Accounts payable and other	14,667	10,987
Accrued liabilities	41,431	44,187
Short-term line of credit	8,087	3,813
Current portion of debt	925	96
Other current liabilities	8,094	5,359
Total current liabilities	73,204	64,442
Debt, net of current portion	13,560	14,279
Derivative warrant liabilities	5,558	1,796
Other non-current liabilities	9,330	12,798
Total liabilities	101,652	93,315
Commitments and contingencies (Note 13)
Stockholders' equity
Preferred Stock, par value $.0001; 50,000,000 shares authorized; no shares issued or outstanding as of September 30, 2022 and June 30, 2022
Additional paid-in capital	336,127	331,386
Accumulated deficit	(287,779)	(287,078)
Total stockholders' equity	48,348	44,308
Total liabilities and stockholders' equity	$ 150,000	$ 137,623

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares	Sep. 30, 2022	Jun. 30, 2022
Preferred stock
Preferred stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Preferred stock, shares authorized (in shares)	50,000,000	50,000,000
Preferred stock, shares issued (in shares)	0	0
Preferred stock, shares outstanding (in shares)	0	0
Common stock
Common stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Common stock, shares authorized (in shares)	200,000,000	200,000,000
Common stock, shares issued (in shares)	3,121,471	1,928,941
Common stock, shares outstanding (in shares)	3,121,471	1,928,941

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations - USD ($) $ in Thousands	3 Months Ended
	Sep. 30, 2022	Sep. 30, 2021
Consolidated Statements of Operations
Product revenue, net	$ 27,655	$ 21,897
Revenue from Contract with Customer, Product and Service	Product	Product
Cost of sales	$ 9,623	$ 9,441
Gross profit	18,032	12,456
Operating expenses
Research and development	1,064	1,652
Selling and marketing	10,102	9,297
General and administrative	7,322	8,216
Impairment expense		19,453
Amortization of intangible assets	1,197	1,537
Total operating expenses	19,685	40,155
Loss from operations	(1,653)	(27,699)
Other Income (expense)
Other expense, net	(1,111)	(40)
Gain on derivative warrant liabilities	2,191
Loss from contingent consideration	(128)	(219)
Total other income (expense)	952	(259)
Loss before income tax	(701)	(27,958)
Income tax benefit		(107)
Net loss	$ (701)	$ (27,851)
Weighted average number of common shares outstanding - basic (in shares)	2,517,906	1,279,865
Weighted average number of common shares outstanding - diluted (in shares)	2,517,906	1,279,865
Basic net loss per common share (in dollars per share)	$ (0.28)	$ (21.76)
Diluted net loss per common share (in dollars per share)	$ (0.28)	$ (21.76)

Condensed Consolidated Statem_2

Condensed Consolidated Statement of Stockholders' Equity - USD ($) $ in Thousands	Common Stock	Additional Paid-in Capital	Accumulated Deficit
Beginning balance at Jun. 30, 2021		$ 315,867	$ (178,299)
Beginning balance (in shares) at Jun. 30, 2021	1,374,520
Increase (Decrease) in Stockholders' Equity
Stock-based compensation		1,519
Stock-based compensation (in shares)	11,000
Issuance of common stock, net of issuance costs		270
Issuance of common stock, net of issuance costs (in shares)	3,075
Tax withholding for stock-based compensation		(6)
Net loss			(27,851)
Ending balance at Sep. 30, 2021		317,650	(206,150)
Ending balance (in shares) at Sep. 30, 2021	1,388,595
Beginning balance at Jun. 30, 2022		331,386	(287,078)
Beginning balance (in shares) at Jun. 30, 2022	1,928,941
Increase (Decrease) in Stockholders' Equity
Stock-based compensation		1,177
Stock-based compensation (in shares)	(1,666)
Issuance of common stock, net of issuance costs		3,564
Issuance of common stock, net of issuance costs (in shares)	1,194,196
Net loss			(701)
Ending balance at Sep. 30, 2022		$ 336,127	$ (287,779)
Ending balance (in shares) at Sep. 30, 2022	3,121,471

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Cash Flows - USD ($) $ in Thousands	3 Months Ended
	Sep. 30, 2022	Sep. 30, 2021
Operating Activities
Net loss	$ (701)	$ (27,851)
Adjustments to reconcile net loss to cash used in operating activities:
Depreciation, amortization and accretion	2,328	2,677
Impairment expense		19,453
Stock-based compensation expense	1,177	1,519
Loss from contingent consideration	128	219
Amortization of senior debt (premium) discount	145	(161)
(Gain) on sale of equipment	(42)
Inventory write-down	82	203
Gain on derivative warrant liabilities	(2,191)
Other noncash adjustments	9	(61)
Changes in operating assets and liabilities:
Accounts receivable	(6,212)	6,525
Inventory	(2,104)	(178)
Prepaid expenses and other current assets	(1,801)	279
Accounts payable and other	3,587	(9,888)
Accrued liabilities	(3,481)	3,326
Other operating assets and liabilities, net	(72)	147
Net cash used in operating activities	(9,148)	(3,791)
Investing Activities
Contingent consideration payment		(50)
Other investing activities	42	(36)
Net cash provided by (used in) investing activities	42	(86)
Financing Activities
Proceeds from issuance of stock and warrants	10,416	307
Payment of stock issuance costs	(793)	(21)
Payment made to fixed payment arrangement	(301)	(2,305)
Proceeds from short-term line of credit	34,791	42,212
Payments made on short-term line of credit	(30,517)	(45,626)
Payments made to borrowings	(26)	(25)
Other financing activities	(13)	(6)
Net cash provided by (used in) financing activities	13,557	(5,464)
Net change in cash, cash equivalents, and restricted cash	4,451	(9,341)
Cash, cash equivalents and restricted cash at beginning of period	19,360	49,901
Cash, cash equivalents and restricted cash at end of period	23,811	40,560
Supplemental cash flow data
Cash paid for interest	565	1,688
Non-cash investing and financing activities:
Fair value of warrants at issuance, net	5,953
Other noncash investing and financing activities	$ 146	16
Fixed payment arrangements included in accrued liabilities		$ 525

Condensed Consolidated Statem_4

Condensed Consolidated Statements of Cash Flows (Parenthetical) $ in Thousands	Sep. 30, 2021 USD ($)
Reconciliation of cash, cash equivalents, and restricted cash to the consolidated balance sheets
Cash and cash equivalents	$ 40,308
Restricted cash	252
Total cash, cash equivalents and restricted cash	$ 40,560

Nature of Business, Financial C

Nature of Business, Financial Condition, Basis of Presentation	3 Months Ended
	Sep. 30, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Nature of Business, Financial Condition, Basis of Presentation	1. Nature of Business, Financial Condition, Basis of Presentation Aytu BioPharma, Inc. (“Aytu”, the “Company” or “we”), is a pharmaceutical company focused on commercializing novel therapeutics and consumer health products. The Company operates through two business segments (i) the Rx segment, consisting of prescription pharmaceutical products and (ii) the Consumer Health segment, which consists of various consumer healthcare products (the “Consumer Health Portfolio”). The Company was originally incorporated as Rosewind Corporation on August 9, 2002 in the State of Colorado and was re-incorporated as Aytu BioScience, Inc in the state of Delaware on June 8, 2015. Following the acquisition of Neos Therapeutics, Inc. (“Neos”) in March 2021, (the “Neos Acquisition”) the Company changed its name to Aytu BioPharma, Inc. On January 6, 2023, the Company effected a reverse stock split in which each common stockholder received one share of common stock for every twenty shares held (“Reverse Stock Split”). All share and per share amounts in this amended quarterly report have been adjusted to reflect the effect of the Reverse Stock Split. The Rx segment primarily consists of two product portfolios: (i) Adzenys XR-ODT (amphetamine) extended-release orally disintegrating tablets and Cotempla XR-ODT (methylphenidate) extended-release orally disintegrating tablets for the treatment of attention deficit hyperactivity disorder (“ADHD”) together the “ADHD Portfolio”), and the “Pediatric Portfolio” consisting of Poly-Vi-Flor and Tri-Vi-Flor, two complementary prescription fluoride-based supplement product lines containing combinations of fluoride and vitamins in various formulations for infants and children with fluoride deficiency, and Karbinal ER, an extended-release antihistamine suspension containing carbinoxamine indicated to treat numerous allergic conditions. The Consumer Health Portfolio consists of over twenty consumer health products competing in large healthcare categories, including allergy, hair regrowth, diabetes support, digestive health, sexual and urological health and general wellness, commercialized through direct-to-consumer and e-commerce marketing channels. The Company’s strategy is to continue building its portfolio of revenue-generating products, leveraging its commercial team’s expertise to build leading brands within large therapeutic markets. As a result of focusing on building the portfolio of revenue-generating products, the Company has indefinitely suspended active development of its clinical development programs including AR101 (enzastaurin) and Healight. As of September 30, 2022, the Company had approximately $23.8 million of cash and cash equivalents and approximately $27.9 million in accounts receivable. The Company’s operations have historically consumed cash and are expected to continue to consume cash. The Company incurred a net loss of approximately $0.7 million and $27.9 million during the three months ended September 30, 2022 and 2021, respectively. The Company had an accumulated deficit of $287.8 million and $287.1 million as of September 30, 2022 and June 30, 2022, respectively. Cash used in operations was $9.1 million and $3.8 million during the three months ended September 30, 2022 and 2021, respectively. In August 2022, the Company completed an underwritten public offering of (i) 1,075,290 shares of its common stock, and, in lieu of common stock to certain investors that so chose, pre-funded warrants to purchase 87,500 shares of its common stock, and (ii) accompanying warrants (the "Common Warrants") to purchase 1,265,547 shares of its common stock (the "Offering") resulting in gross and net proceeds of $10.0 million and $9.1 million, respectively, assuming none of the accompanying Common Warrants issued in the Offering are exercised. The pre-funded warrants were exercised in full in August 2022. The Company intends to use the net proceeds from the Offering for growth of the Company’s commercial business, and for working capital and general corporate purposes. As the Company does not have sufficient cash and cash equivalents as of September 30, 2022 to cover its cash needs for the twelve months following the filing date of this Quarterly Report on Form 10-Q/A, there exists substantial doubt about the Company’s ability to continue as a going concern. The condensed consolidated financial statements do not include adjustments that might be necessary if the Company is unable to continue as a going concern. Management plans to mitigate the conditions that raise substantial doubt about its ability to continue as a going concern are primarily focused on increasing revenue, reducing expenses associated with research and development and raising additional capital through public or private equity or debt offerings or monetizing assets in order to meet its obligations. Management believes that the Company has access to capital resources, however, the Company cannot provide any assurance that it will be able to raise additional capital, monetize assets or obtain new financing on commercially acceptable terms. If the Company is unable to secure additional capital, it may be required to curtail its operations or delay the execution of its business plan. Alternatively, any efforts by the Company to reduce its expenses may adversely impact its ability to sustain revenue-generating activities and delay the progress of its developmental product candidates or otherwise operate its business. As a result, there can be no assurance that the Company will be successful in implementing its plans to alleviate this substantial doubt about its ability to continue as a going concern. Basis of Presentation. Also see Note 2 – Previously Reported Financial Statements the immaterial correction of an error in the condensed consolidated balance sheet and the condensed consolidated statement of stockholders’ equity for as of June 30, 2022. Prior Period Reclassification.

Significant Accounting Policies

Significant Accounting Policies	3 Months Ended
Significant Accounting Policies	Sep. 30, 2022
Accounting Policies [Abstract]
Significant Accounting Policies	2. Significant Accounting Policies Use of Estimates Management uses estimates and assumptions relating to reporting amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements and the reported amount of revenues and expenses during the reporting period. In the accompanying condensed consolidated financial statements, estimates are used for, but not limited to, stock-based compensation, revenue recognition, allowance for doubtful accounts, determination of variable consideration for accruals of chargebacks, administrative fees and rebates, government rebates, returns and other allowances, allowance for inventory obsolescence, valuation of financial instruments and intangible assets, accruals for contingent liabilities, fair value of long-lived assets, the value of goodwill, income tax provision, deferred taxes and valuation allowance, determination of right-of-use assets and lease liabilities, purchase price allocations, the depreciable lives of long-lived assets, classification of warrants equity versus liability, and valuation of derivative warrant liability. Because of the uncertainties inherent in such estimates, actual results may differ from those estimates. Management periodically evaluates estimates used in the preparation of the financial statements for reasonableness. Previously Reported Financial Statements The classification of certain of the Company’s warrants were previously recorded as equity. These warrants according to GAAP should have been classified as derivative warrant liabilities at fair value and marked to market at each reporting period, with changes in fair value recorded in earnings. The affected filing periods are the quarterly unaudited financial statements as of March 31, 2022 and September 30, 2022, and the audited financial statements as of June 30, 2022. SEC Staff Accounting Bulletin No. 99, “Materiality,” and FASB, Statement of Financial Accounting Concepts No. 2 “Qualitative Characteristics of Accounting Information” indicate that quantifying and aggregating errors is only the beginning of an analysis of materiality and that both quantitative and qualitative factors must be considered in determining whether individual errors are material. The Company evaluated the corrections and have determined that the impact was not material for the periods ended March 31, 2022 and June 30, 2022, but is material for the period ended September 30, 2022. The assessment resulted in the amendment of the previously reported financial statements reported in the Company’s first quarter of 2023 Form 10-Q. The balance sheet as at June 30, 2022 included in this amended Form 10-Q/A has been adjusted for the immaterial correction of this error. In addition, financial statements for the period ended March 31, 2022 and for the fiscal year ended June 30, 2022 will be adjusted at the time of their reissuance. The condensed consolidated financial statements and certain of the notes to the condensed consolidated financial statements as of and for the three months ended September 30, 2022 have been restated to reflect the corrections. The impact of the restatement for the period ended September 30, 2022 is shown in the tables below and did not change the Company’s reported total assets, cash and cash equivalents, operating expenses, operating losses or cash flows from operations. As of September 30, 2022 As Previously Reported Adjustment As Restated (in thousands) Derivative warrant liability $ — $ 5,558 $ 5,558 Total liabilities 96,094 5,558 101,652 Additional paid-in capital 345,253 (9,126) 336,127 Accumulated deficit (291,353) 3,574 (287,779) Total stockholders’ equity 53,906 (5,558) 48,348 Three Months Ended September 30, 2022 As Previously Reported Adjustment As Restated (in thousands) Statement of Operation data Gain on derivative warrant liabilities $ — $ 2,191 $ 2,191 Total other (expense) income (1,228) 2,180 952 Loss before income tax (2,881) 2,180 (701) Net loss (2,881) 2,180 (701) Basic and diluted net loss per common share (1.14) 0.86 (0.28) Statement of Cash Flow data Net loss $ (2,881) $ 2,180 $ (701) Gain on derivative warrant liabilities — 2,191 2,191 Net loss by segment Rx Segment $ (2,054) $ 2,180 $ 126 Consumer Health Segment (827) — (827) Consolidated net loss (2,881) 2,180 (701) The condensed consolidated balance sheet and the condensed consolidated statement of stockholders’ equity as of June 30, 2022 have been adjusted for comparative purposes. The impact of the immaterial correction of an error for as of June 30, 2022 is shown in the table below. As of June 30, 2022 As Previously Reported Adjustment As Adjusted (in thousands) Derivative warrant liability $ — $ 1,796 $ 1,796 Total liabilities 91,531 1,784 93,315 Additional paid-in capital 334,560 (3,174) 331,386 Accumulated deficit (288,472) 1,394 (287,078) Total stockholders’ equity 46,092 (1,784) 44,308 Warrants The Company accounts for warrants as either equity-classified or liability-classified instruments based on an assessment of the warrant’s specific terms and applicable authoritative guidance in Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) 480, Distinguishing Liabilities from Equity (“ASC 480”) and ASC 815, Derivatives and Hedging (“ASC 815”). The assessment considers whether the warrants are freestanding financial instruments pursuant to ASC 480, meet the definition of a liability pursuant to ASC 480, and whether the warrants meet all of the requirements for equity classification under ASC 815, including whether the warrants are indexed to the Company’s own common shares and whether the warrant holders could potentially require “net cash settlement” in a circumstance outside of the Company’s control, among other conditions for equity classification. This assessment, which requires the use of professional judgment, is conducted at the time of warrant issuance and as of each subsequent quarterly period end date while the warrants are outstanding. Liability and equity classified warrants are valued using either a Black-Scholes option Income Taxes The Company calculates its quarterly income tax provision based on estimated annual effective tax rates applied to ordinary income (or loss) and other known items computed and recognized when they occur. There have been no changes in tax law affecting the tax provision during the three months ended September 30, 2022. An ownership change (generally a 50% change in equity ownership over a three-year period) could limit the Company’s ability to offset, post-change, U.S. federal taxable income. Section 382 of the Code imposes an annual limitation on the amount of post-ownership change taxable income a corporation may offset with pre-ownership change net operating loss carryforwards and certain recognized built-in losses. The Company believes that previous acquisitions, financing transactions, and equity ownership changes in the past five years may have caused an ownership change results in a limitation of its ability to use the pre-acquisition net operating loss carryovers. The ownership change scenario could result in increased future tax liability. The company is in the process of analyzing the impact of any possible ownership change the result of which may be a change to the Company’s net deferred tax asset or liability position. Impairment of Other Intangibles Assets Acquired in-process research and development (“IPR&D) is an intangible asset classified as an indefinite-lived asset until the completion or abandonment of the associated research and development (“R&D”) effort. In periods after the acquired IPR&D, the Company may (1) continue internal R&D efforts associated with the acquired assets or collaborate with another party in R&D efforts; (2) dispose of the assets through sale; (3) outlicense the assets; (4) decide to temporarily postpone further development; or (5) abandon R&D efforts. IPR&D asset may be subject to different subsequent accounting treatment depending on the course of action chosen by the Company with respect to the asset. If the Company changes strategies related to the IPR&D the asset could potentially be impaired. Recent Adopted Accounting Pronouncements Reference Rate Reform. , Reference Rate Reform (Topic 848): “Facilitation of the Effects of Reference Rate Reform on Financial Reporting” Earnings Per Share. In May 2021, the FASB issued ASU 2021-04, “ Earnings Per Share (Topic 260), Debt – Modifications and Extinguishments (Subtopic 470-50), Compensation – Stock Compensation (Topic 718), and Derivatives and Hedging – Contracts in Entity’s Own Equity (Subtopic 815-40): Issuer’s Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options ”. The amendments in ASU 2021-04 provide guidance to clarify and reduce diversity in an issuer’s accounting for modifications or exchanges of freestanding equity-classified written call options (for example, warrants) that remain equity classified after modification or exchange. ASU 2021-04 is effective for all entities for fiscal years beginning after December 15, 2021, and interim periods within those fiscal years, with early adoption permitted. The adoption of ASU 2021-04 and related updates did not have a material impact on its condensed consolidated financial statements. Recent Accounting Pronouncements Not Yet Adopted Debt—Debt with Conversion and Other Options. Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging— Contracts in Entity’s Own Equity (Subtopic 815-40)— “Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity” smaller reporting companies, as defined by the Securities and Exchange Commission (”SEC”), for the fiscal years beginning after December 15, 2023, including interim periods within those fiscal years. Early adoption is permitted through a modified retrospective or full retrospective method. The Company will adopt the guidance on July 1, 2023 and does not expect the adoption of the standard to have any material impact on the Company’s condensed consolidated financial position and results of operations. Financial Instruments Credit Losses. ASU 2016-13, “Financial Instruments – Credit Losses” For a complete set of the Company’s significant accounting policies, refer to our Annual Report on Form 10-K for the fiscal year ended June 30, 2022. There have been no significant changes to the Company’s significant accounting policies during the three months ended September 30, 2022.

Revenues from Contracts with Cu

Revenues from Contracts with Customers	3 Months Ended
Revenues from Contracts with Customers	Sep. 30, 2022
Revenue from Contract with Customer [Abstract]
Revenues from Contracts with Customers	3. Revenues from Contracts with Customers Contract Balances Revenues by Product Portfolio. Three Months Ended September 30, 2022 2021 ADHD Portfolio $ 11,585 $ 9,327 Pediatric Portfolio 6,558 3,798 Consumer Health Portfolio 9,003 8,014 Other 509 758 Consolidated revenue $ 27,655 $ 21,897 Other consists of non-core products identified to be discontinued or divested including Cefaclor, Flexichamber, generic Tussionex, Tuzistra XR, and ZolpiMist. (see Note 7 – Goodwill and Other Intangible Assets). Revenues by Geographic location . Three Months Ended September 30, 2022 2021 (In thousands) U.S. $ 27,476 $ 21,106 International 179 791 Total net revenue $ 27,655 $ 21,897

Inventories

Inventories	3 Months Ended
Inventories	Sep. 30, 2022
Inventory Disclosure [Abstract]
Inventories	4. Inventories Inventories consist of raw materials, work in process and finished goods and are recorded at the lower of cost or net realizable value, with cost determined on a first-in, first-out basis. The Company periodically reviews the composition of its inventories to identify obsolete, slow-moving or otherwise unsaleable items. In the event that such items are identified and there are no alternate uses for the inventory, the Company will record a charge to reduce the value of the inventory to net realizable value in the period that the impairment is first recognized. The Company incurred charges of $0.1 million and $0.2 million to reduce the carrying value of inventory to net realizable value during the three months ended September 30, 2022 and 2021, respectively. Inventory balances consist of the following: September 30, June 30, 2022 2022 (In thousands) Raw materials $ 2,113 $ 1,814 Work in process 2,374 1,838 Finished goods 8,384 7,197 Inventory, net $ 12,871 $ 10,849

Property and Equipment

Property and Equipment	3 Months Ended
Property and Equipment	Sep. 30, 2022
Property, Plant and Equipment [Abstract]
Property and Equipment	5. Property and Equipment Properties and equipment are recorded at cost and depreciated on a straight-line basis over the assets estimated economic life. Leasehold improvements are amortized over the shorter of the estimated economic life or remaining lease term. Property and equipment consist of the following: September 30, June 30, 2022 2022 (In thousands) Manufacturing equipment $ 2,449 $ 2,487 Leasehold improvements 999 999 Office equipment, furniture and other 1,128 1,128 Lab equipment 832 832 Property and equipment, gross 5,408 5,446 Less accumulated depreciation and amortization (2,736) (2,421) Property and equipment, net $ 2,672 $ 3,025 Depreciation and amortization expense was $0.3 million and $0.4 million for the three months ended September 30, 2022 and 2021, respectively.

Leases

Leases	3 Months Ended
Leases	Sep. 30, 2022
Leases [Abstract]
Leases	6. Leases The Company has entered into various operating lease agreements for certain of its offices, manufacturing facilities and equipment, and finance lease agreements for certain equipment. These leases have original lease periods expiring between 2022 and 2027. Most leases include one or more options to renew, and the exercise of a lease renewal option typically occurs at the discretion of both parties. Certain leases also include options to purchase the leased property. The Company’s lease agreements generally do not contain any material residual value guarantees or material restrictive covenants. The components of lease expenses are as follows: Three Months Ended September 30, 2022 2021 Statement of Operations Classification (In thousands) Lease cost: Operating lease cost $ 222 $ 296 Operating expenses Short-term lease cost 160 39 Operating expenses Finance lease cost: Amortization of leased assets 18 18 Cost of sales Interest on lease liabilities 3 4 Other (expense), net Total net lease cost $ 403 $ 357 Supplemental balance sheet information related to leases is as follows: September 30, June 30, Balance Sheet Classification 2022 2022 (In thousands) Assets: Operating lease assets $ 2,976 $ 3,271 Operating lease right-of-use asset Finance lease assets 238 256 Property and equipment, net Total leased assets $ 3,214 $ 3,527 Liabilities: Current: Operating leases $ 1,252 $ 1,227 Other current liabilities Finance leases 92 96 Current portion of debt Non-current Operating leases 1,768 2,090 Other non-current liabilities Finance leases 62 84 Debt, net of current portion Total lease liabilities $ 3,174 $ 3,497 Remaining lease term and discount rate used are as follows: September 30, June 30, 2022 2022 Weighted-Average Remaining Lease Term (years) Operating lease assets 2.39 2.63 Finance lease assets 1.48 1.73 Weighted-Average Discount Rate Operating lease assets 7.54 % 7.48 % Finance lease assets 6.43 % 6.43 % Supplemental cash flow information related to lease is as follows: Three Months Ended September 30, 2022 2021 (In thousands) Cash flow classification of lease payments: Operating cash flows from operating leases $ 357 $ 282 Operating cash flows from finance leases $ 3 $ 4 Financing cash flows from finance leases $ 27 $ 25 As of September 30, 2022, the maturities of the Company’s future minimum lease payments were as follows: Operating Finance (In thousands) 2023 (remaining 9 months) $ 1,079 $ 75 2024 1,379 87 2025 749 — 2026 90 — 2027 46 — Total lease payments 3,343 162 Less: Imputed interest (323) (8) Lease liabilities $ 3,020 $ 154

Goodwill and Other Intangible A

Goodwill and Other Intangible Assets	3 Months Ended
Goodwill and Other Intangible Assets	Sep. 30, 2022
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill and Other Intangible Assets	7. Goodwill and Other Intangible Assets There were no impairments of intangible assets during the three months ended September 30, 2022. During the three months ended September 30, 2021, the Company’s market capitalization significantly declined. As a result of the decline in market capitalization and qualitative and quantitative analysis the Company recognized an impairment of goodwill of $19.5 million. The following table provides the summary of the Company’s intangible assets as of September 30, 2022 and June 30, 2022, respectively. September 30, 2022 Weighted- Gross Net Average Carrying Accumulated Carrying Remaining Amount Amortization Impairment Amount Life (in years) (In thousands) Definite-lived intangibles: Acquired product technology rights 45,400 (8,471) (3,224) 33,705 12.04 Acquired technology right 30,200 (2,722) — 27,478 15.50 Acquired product distribution rights 11,354 (3,857) (2,172) 5,325 7.35 86,954 (15,050) (5,396) 66,508 13.10 Indefinite-lived intangibles: Acquired in-process R&D 2,600 — — 2,600 Indefinite-lived 2,600 — — 2,600 Total $ 89,554 $ (15,050) $ (5,396) $ 69,108 13.10 June 30, 2022 Weighted- Gross Net Average Carrying Accumulated Carrying Remaining Amount Amortization Impairment Amount Life (in years) (In thousands) Definite-lived intangibles: Acquired product technology rights $ 45,400 $ (7,667) $ (3,224) $ 34,509 12.33 Acquired technology right 30,200 (2,278) — 27,922 15.75 Acquired product distribution rights 11,354 (3,581) (2,172) 5,601 7.60 Other intangible assets 4,666 (3,004) (1,662) — — 91,620 (16,530) (7,058) 68,032 13.35 Indefinite-lived intangibles: Acquired in-process R&D 2,600 — — 2,600 Indefinite-lived 2,600 — — 2,600 Total $ 94,220 $ (16,530) $ (7,058) $ 70,632 13.35 The following table summarizes the estimated future amortization expense to be recognized over the next five years and periods thereafter: September 30, (In thousands) 2023 (remaining 9 months) $ 4,563 2024 6,074 2025 5,934 2026 5,683 2027 5,652 2028 5,552 Thereafter 33,050 Total future amortization expense $ 66,508 Product Technology Rights The acquired product technology rights are related to the rights to production, supply and distribution agreements of various products pursuant to the acquisitions of the Pediatric Portfolio in November 2019 and the Neos Acquisition in March 2021. Karbinal® ER. Poly-Vi-Flor and Tri-Vi-Flor. ADHD Portfolio. Developed Technology Right TRRP Technology. Product Distribution Rights and Customer List In connection with the Innovus Acquisition, the Company obtained 35 products with a combination of over 300 registered trademarks and/or patent rights and customer lists. As of June 30, 2022, the customer list intangible asset was fully amortized. In-Process R&D IPR&D – NT0502. Certain of the Company’s amortizable intangible assets include renewal options, extending the expected life of the asset. The renewal periods range between approximately 1 to 20 years depending on the license, patent or other agreement. Renewals are accounted for when they are reasonably assured. Intangible assets are amortized using the straight-line method over the estimated useful lives. Amortization expense of intangible assets was $1.5 million for the three months ended September 2022 and $2.1 million during the three months ended September 30, 2021, respectively.

Accrued Liabilities

Accrued Liabilities	3 Months Ended
Accrued Liabilities	Sep. 30, 2022
Accrued Liabilities, Current [Abstract]
Accrued Liabilities	8. Accrued liabilities Accrued liabilities consist of the following: September 30, June 30, 2022 2022 (In thousands) Accrued savings offers $ 11,801 $ 12,711 Accrued program liabilities 8,080 9,468 Product return reserve 5,826 5,770 Accrued employee compensation 5,679 4,765 Accrued customer and product related fees 6,832 7,817 Other accrued liabilities 3,213 3,656 Total accrued liabilities $ 41,431 $ 44,187 Savings offers represent programs for the Company’s patients covered under commercial payor plans in which the cost of a prescription to such patients is discounted. Customer and product related fees include accrued expenses and deductions for rebates, wholesaler chargebacks and fees, and other product-related fees and deductions. Other accrued liabilities consist of accrued license fees, legal settlements, professional fees, credit card liabilities, taxes payable, and samples expense .

Other Liabilities

Other Liabilities	3 Months Ended
Other Liabilities	Sep. 30, 2022
Other Liabilities Disclosure [Abstract]
Other Liabilities	9. Other Liabilities September 30, June 30, 2022 2022 (In thousands) Fixed payment arrangements $ 12,472 $ 13,051 Contingent value rights 706 578 Contingent consideration 423 396 Operating lease liabilities 3,020 3,317 Other 803 815 Total other liabilities 17,424 18,157 Less: current portion (8,094) (5,359) Total other liabilities, noncurrent $ 9,330 $ 12,798 Fixed Payment Arrangements. Fixed payment arrangements represent obligations to an investor assumed as part of the acquisition of products from Cerecor, Inc. in 2019, including fixed and variable payments. These obligations included fixed monthly payments equal to $0.1 million from November 2019 through January 2021 plus $15.0 million due in January 2021, of which $15.0 million was paid down early in June 2021. Monthly variable payments due to the same investor are equal to 15.0% of net revenue generated from a subset of the Pediatric Portfolio, subject to an aggregate monthly minimum of $0.1 million, except for January 2021, when a one-time payment of $0.2 million was due and paid. The variable payment obligation was to continue until the earlier of (i) aggregate variable payments of approximately $9.3 million have been made or (ii) February 12, 2026. In addition, the Company assumed fixed, product minimums royalties of approximately $2.1 million per annum through February 2023. On June 21, 2021, the Company entered into a Waiver, Release and Consent pursuant to which the Company paid $2.8 million to the investor in early satisfaction of the fixed obligation. The Company agreed to pay the remaining fixed obligation of $3.0 million in six equal quarterly payments of $0.5 million each over six quarters beginning September 30, 2021. The Company accounted the Waiver, Release and Consent as a debt and remeasured the related liabilities using a discounted cash flow model. As of September 30, 2022, the fixed payment arrangement was $1.0 million on our condensed consolidated balance sheet. In addition, the Company acquired a Supply and Distribution Agreement with Tris (the “Karbinal Agreement”), under which the Company is granted the exclusive right to distribute and sell the product in the United States. The initial term of the Karbinal Agreement was 20 years. The Company will pay Tris a royalty equal to 23.5% of net sales. The Karbinal Agreement also contains minimum unit sales commitments, which is based on a commercial year that spans from August 1 through July 31, of 70,000 units annually through 2025. The Company is required to pay Tris a royalty make whole payment of $30 for each unit under the 70,000-unit annual minimum sales commitment through 2025. The Karbinal Agreement make-whole payment is capped at $2.1 million each year. The annual payment is due in August of each year. The Karbinal Agreement also has multiple commercial milestone obligations that aggregate up to $3.0 million based on cumulative net sales, the first of which is triggered at $40.0 million of net revenues. On May 12, 2022, the Company entered into an agreement with Tris to terminate the License, Development, Manufacturing and Supply Agreement dated November 2, 2018 (the “License Agreement”). Pursuant to such termination, the Company agreed to pay Tris a total of approximately $9.0 million, which reduced our total liability for minimum payments by approximately $8.0 million from the original License Agreement. The settlement payment will be paid in three installments from December 2022 through July 2024. As of September 30, 2022, the balance was $6.9 million on the condensed consolidated balance sheet. Contingent Value Rights. Contingent value rights (“CVRs”) represent contingent consideration related to the Company’s 2020 acquisition of Innovus of up to $16.0 million payable upon attainment of future performance milestones. Consideration can be satisfied in up to 470,000 shares of the Company’s common stock, or cash either upon the option of the Company or in the event there are insufficient shares available to satisfy such obligations. As of September 30, 2022, up to $5.0 million of future milestone payments potentially remain. As of September 30, 2022 and June 30, 2022, the CVRs were revalued at $0.7 million and $0.6 million, respectively. During the three months ended September 30, 2022 and 2021, the Company recognized a loss of $0.1 million and a gain of $0.1 million, respectively, in the condensed consolidated statements of operations related to the changes in fair values of CVRs. Contingent Consideration . Contingent consideration represents the fair value of potential future payments in connection with acquisitions that are contingent upon the occurrence of a particular event or events. The Company records an obligation for such contingent payments at fair value on the acquisition date. Subsequent changes in the fair value of contingent consideration obligations are recognized in the condensed consolidated statements of income. As of September 30, 2022, the Company’s contingent consideration liabilities consist primarily of obligations related to the Company’s 2020 acquisition of Innovus. In connection with the acquisition, the Company assumed a license agreement for patents and technology under which Innovus will pay a total milestone payment of $50,000 every other year beginning on July 1, 2021 for a total payment of $0.2 million. The fair value was based on a discounted value of the future contingent payment using a 26% discount rate based on the estimated risk that the milestones would be achieved. In addition, Innovus recognized approximately $0.2 million in product related contingent consideration. The fair value was based on a discounted value of the future contingent payment using a 30% discount rate based on the estimated risk that the milestones are achieved. As of September 30, 2022 and June 30, 2022, the contingent consideration balance was $0.4 million and $0.4 million, respectively. Prior to September 30, 2022, the Company’s contingent consideration liabilities included obligations under licensing arrangements for Tuzistra XR . The royalty and make-whole milestone payments related to licensing agreements with Tris for Tuzistra XR were being accounted for as contingent consideration and revalued at each reporting period. As a result of the discontinuation of commercializing Tuzistra and the settlement agreement with Tris, the Company concluded that the product milestone payments underlying the contingent consideration liability ceased to exist. The Company reversed the remaining contingent consideration liabilities of $8.5 million and recorded a liability of $7.6 million related to the settlement payments payable to Tris for termination of the Tuzistra licensing agreement. The settlement payments are included in fixed payment arrangements at their present value using the Company’s estimated borrowing rate. Prior to March 31, 2022, the royalty payments related to licensing agreements with Magna Pharmaceuticals, Inc. (“Magna”) for ZolpiMist were being accounted for as contingent consideration and revalued at each reporting period. As a result of the discontinuation of commercializing ZolpiMist, the Company concluded that the royalty-based product milestone payments underlying the contingent consideration liability ceased to exist. As of March 31, 2022, the Company reversed the remaining contingent consideration liabilities of $0.6 million and recorded the $50,000 payment due for termination of the Manga licensing agreements in other current liabilities. During the three months ended September 30, 2022 and 2021, the Company recognized a net a loss of $0 million and $0.2 million, respectively, from the changes in fair values of contingent considerations. The total accretion expense related to these contingent considerations was approximately $0.1 million for both the three months ended September 30, 2022 and 2021. Other. Other consist of taxes payable and deferred cost related to our technology transfer.

Line of Credit

Line of Credit	3 Months Ended
Line of Credit	Sep. 30, 2022
Debt Disclosure [Abstract]
Line of Credit	10. Line of Credit Upon closing of the Neos Acquisition in March 2021, the Company assumed obligations under the secured credit agreement that Neos had entered into with Eclipse Business Capital LLC (f/k/a Encina Business Credit, LLC) (“Eclipse”) as agent for the lenders (the “Eclipse Loan Agreement”). Under the Eclipse Loan Agreement, Eclipse extended up to $25.0 million in secured revolving loans to Neos (the “Revolving Loans”), of which up to $2.5 million was available for short-term swingline loans, against 85% of eligible accounts receivable. The Revolving Loans thereunder accrued at variable interest through maturity at the one-month Secure Overnight Financing Rate (“SOFR”), plus 4.50%. The Eclipse Loan Agreement included an unused line fee of 0.50% of the average unused portion of the maximum revolving facility amount during the immediately preceding month. Interest is payable monthly in arrears. The original maturity date under the Eclipse Loan Agreement was May 11, 2022. In connection with the Avenue Capital Agreement, described in Note 11— Long-term debt below, the Company entered into a Consent, Waiver and Second Amendment to Eclipse Loan Agreement, dated as of January 26, 2022 (together, the “Eclipse Second Amendment”). Pursuant to the Eclipse Second Amendment, Eclipse (i) consented to Aytu and certain of its subsidiaries joining as obligors to the Revolving Loans provided by the Eclipse Loan Agreement, (ii) consented to the Company entering into the Avenue Capital Agreement, (iii) extended the maturity date of the Eclipse Loan Agreement to January 26, 2025, (iv) removed the requirement for the Company to comply with the ongoing fixed charge coverage ratio financial covenant applicable to the borrowers under the Eclipse Loan Agreement, (v) consented to the first priority lien granted by Aytu in favor of the Avenue Capital Agent, (vi) reduced the maximum availability under the Revolving Loans from $25.0 million to $12.5 million minus a $3.5 million availability block, (vii) increased the availability block from $1.0 million to $3.5 million, (viii) consented to the full repayment under the Deerfield Facility, defined below, and (ix) made certain other modifications to conform to the Avenue Capital Agreement and to reflect the consummation of the transactions thereof, in each case subject to the terms and conditions of the Eclipse Second Amendment. In the event that, for any reason, all or any portion of the Eclipse Loan Agreement is terminated prior to the scheduled maturity date, in addition to the payment of all outstanding principal and unpaid accrued interest, the Company is required to pay a fee equal to (i) 2.0% of the Revolving Loans commitment if such event occurs on or before January 26, 2023, (ii) 1.0% of the Revolving Loans commitment if such event occurs after January 26, 2023 but on or before January 26, 2024, and (iii) 0.5% of the Revolving Loans commitment if such event occurs after January 26, 2024 but on or before January 26, 2025. The Company may permanently terminate the Eclipse Loan Agreement at any time with at least five The Eclipse Loan Agreement contains customary affirmative covenants, negative covenants and events of default, as defined in the agreement, including covenants and restrictions that, among other things, require the Company to satisfy certain capital expenditure limitations and other financial covenants, and restrict the Company’s ability to incur liens, incur additional indebtedness, make certain dividends and distributions with respect to equity securities, engage in mergers and acquisitions or make asset sales without the prior written consent of Eclipse. A failure to comply with these covenants could permit Eclipse to declare the Company’s obligations under the Eclipse Loan Agreement, together with accrued interest and fees, to be immediately due and payable, plus any applicable additional amounts relating to a prepayment or termination, as described above. As of September 30, 2022, the Company was in compliance with the covenants under the Eclipse Loan Agreement as amended. The Company’s obligations under the Eclipse Loan Agreement are secured by substantially all of the Company’s assets, with a first priority lien in favor of Eclipse on the ABL Priority Collateral, and a second priority lien in favor of Eclipse on the Term Loan Priority Collateral, as each is defined in the Replacement Term Loan Intercreditor Agreement, as defined in the Eclipse Loan Agreement, as amended by the Eclipse Second Amendment. Total interest expense on the Revolving Loans, including amortization of deferred financing costs, was $0.1 million for both the three months ended September 30, 2022 and 2021. As of September 30, 2022 and June 30, 2022, the outstanding Revolving Loans under the Eclipse Loan Agreement, as amended, were $8.1 million and $3.8 million, respectively.

Long-term Debt

Long-term Debt	3 Months Ended
Long-term Debt	Sep. 30, 2022
Long-term Debt
Long-term Debt	11. Long-term Debt Avenue Capital Loan: Pursuant to the Avenue Capital Agreement, the Company will make interest only payments for the first 18 months following the Closing Date (“Interest-only Period”). The Interest-only Period could be extended automatically without any action by any party for six months provided, as of the last day of the Interest-only Period then in effect, the Company received, prior to June 15, 2023, a specified amount of net proceeds from the sale and issuance of its equity securities (“Interest-only Milestone 1”). The Interest-only Period could further be extended automatically without any action by any party for an additional twelve months provided, the Company has achieved, prior to December 31, 2023, (i) Interest-only Milestone 1 and (ii) a specified amount of trailing 12 months revenue (“Interest-only Milestone 2”) as of the date of determination. See Note 20 Subsequent Events for further detail on extension of interest only period. In the event the Company prepays the outstanding principal prior to the maturity date, the Company will pay Avenue Capital a fee equal to (i) 3.0% of the loan if such event occurs on or before January 26, 2023, (ii) 2.0% of the loan if such event occurs after January 26, 2023 but on or before January 26, 2024, and (iii) 1.0% of the loan if such event occurs after January 26, 2024 but before January 26, 2025. In addition, upon the payment in full of the obligations, the Company shall pay to Avenue Capital a fee in the amount of $0.6 million (“Final Payment”). The Company’s obligations under Avenue Capital Agreement are secured by substantially all of the Company’s assets, with a first priority lien in favor of the Avenue Capital Agent on the Term Loan Priority Collateral, and a second priority lien in favor of the Avenue Capital Agent on the ABL Priority Collateral, as each is defined in the Intercreditor Agreement, as defined in the Avenue Capital Agreement. The Avenue Capital Agreement contains customary affirmative covenants, negative covenants and events of default, as defined in the agreement, including covenants and restrictions that, among other things, require the Company to satisfy certain capital expenditure limitations and other financial covenants, and restricts the Company’s ability to incur liens, incur additional indebtedness, make certain dividends and distributions with respect to equity securities, engage in mergers and acquisitions or make asset sales without the prior written consent of the Avenue Capital Lenders. A failure to comply with these covenants could permit the Avenue Capital Lenders to declare the Company’s obligations under the agreement, together with accrued interest and fees, to be immediately due and payable, plus any applicable additional amounts relating to a prepayment or termination, as described above. As of September 30, 2022, the Company was in compliance with the covenants under the Avenue Capital Agreement. On January 26, 2022 (“Issuance Date”), as consideration for entering into the Avenue Capital Agreement, the Company issued warrants to the Avenue Capital Lenders to purchase shares of common stock at an exercise price equal to $24.20 per share (the “Avenue Capital Warrants”). The Avenue Capital Warrants provided that in the event the Company were to engage in an equity offering at a price lower than $24.20 prior to June 30, 2022, the exercise price would be adjusted to the effective price of such equity offering and the number of shares of common stock to be issued under the Avenue Capital Warrants would be adjusted as set forth in the agreement. The Avenue Capital Warrants were immediately exercisable and expire on January 31, 2027. On In addition to the debt discounts discussed above, the Company also incurred $0.4 million loan origination, legal and other fees. The debt discount and issuance costs are being amortized over the term of the loan, using the effective interest method resulting in an effective rate of 15.37%. Total interest expense includes debt discount amortization, was $0.6 million and $0 million for the three months ended September 30, 2022 and 2021, respectively. Long-term debt consists of the following: September 30, 2022 (In thousands) Long-term debt, due on January 26, 2025 $ 15,000 Long-term, final payment fee 638 Unamortized discount and issuance costs (1,306) Financing leases, maturing through May 2024 154 Total debt 14,485 Less: current portion (925) Non-current portion of debt $ 13,560 Future principal payments of long-term debt, including financing leases, are as follows: September 30, (In thousands) 2023 $ 92 2024 8,395 2025 7,304 Future principal payments 15,791 Less unamortized discount and issuance costs (1,306) Less current portion (925) Non-current portion of debt $ 13,560

Fair Value Considerations

Fair Value Considerations	3 Months Ended
Fair Value Considerations	Sep. 30, 2022
Fair Value Disclosures [Abstract]
Fair Value Considerations	12. Fair Value Considerations We determine the fair value of financial and non-financial assets and liabilities using the fair value hierarchy, which establishes three levels of inputs that may be used to fair value as follows: ● Level 1: Inputs that reflect unadjusted quoted prices in active markets that are accessible to Aytu for identical assets or liabilities; ● Level 2: Inputs that include quoted prices for similar assets and liabilities in active or inactive markets or that are observable for the asset or liability either directly or indirectly; and ● Level 3: Unobservable inputs that are supported by little or no market activity. The Company’s financial instruments include cash and cash equivalents, restricted cash, accounts receivable, accounts payable, accrued liabilities, warrant derivative liability contingent consideration liabilities, and short-term and long-term debt. The carrying amounts of certain short-term financial instruments, including cash and cash equivalents, restricted cash, accounts receivable, accounts payable and accrued liabilities approximate their fair value due to their short maturities. Short-term and long-term debt are reported at their amortized costs on our consolidated balance sheets. The remaining financial instruments and derivative warrant liabilities are reported on our consolidated balance sheets at amounts that approximate current fair values. The Company’s policy is to recognize transfers in and/or out of fair value hierarchy as of the date in which the event or change in circumstances caused the transfer. There were no transfers between Level 1, Level 2 and Level 3 in the periods presented. Recurring Fair Value Measurements The following table presents the Company’s financial assets and liabilities that were accounted for at fair value on a recurring basis as of September 30, 2022 and June 30, 2022, by level within the fair value hierarchy. Fair Value Measurements at September 30, 2022 Fair Value at September 30, 2022 (Level 1) (Level 2) (Level 3) (In thousands) Assets: Cash and cash equivalents $ 23,811 $ 23,811 $ — $ — Total $ 23,811 $ 23,811 $ — $ — Liabilities: Contingent consideration $ 423 $ — $ — $ 423 CVR liability 706 — — 706 Derivative warrant liabilities (As Restated) 5,558 — — 5,558 Total $ 6,687 $ — $ — $ 6,687 Fair Value Measurements at June 30, 2022 Fair Value at June 30, 2022 (Level 1) (Level 2) (Level 3) (In thousands) Assets: Cash and cash equivalents $ 19,360 $ 19,360 $ — $ — Total $ 19,360 $ 19,360 $ — $ — Liabilities: Contingent consideration $ 396 $ — $ — $ 396 CVR liability 578 — — 578 Derivative warrant liabilities 1,796 — — 1,796 Total $ 2,770 $ — $ — $ 2,770 Summary of Level 3 Input Changes The following table sets forth a summary of changes to those fair value measures using Level 3 inputs for the three months ended September 30, 2022: CVR Contingent Derivative Fixed Payment Liability Consideration Warrant Liabilities Arrangement (In thousands) Balance as of June 30, 2022 $ 578 $ 396 $ 1,796 $ 13,051 Included in earnings 128 27 (2,191) 446 Purchases, issues, sales and settlements: Issues — — 5,953 — Settlements — — — (1,025) Balance as of September 30, 2022 $ 706 $ 423 $ 5,558 $ 12,472 Significant Assumptions Significant assumptions used in valuing CVRs were as follows: September 30, 2022 Leveraged Beta 0.84 Market risk premium 6.22 % Risk-free interest rate 4.09 % Discount 21.50 % Company specific discount 10.00 % Significant assumptions used in valuing August 9, 2022 Expected volatility 89.89 % Equivalent term (years) 4.11 Risk-free rate 3.09 % Dividend yield 0.00 % Significant assumptions used in valuing September 30, 2022 Expected volatility 87.33 % Equivalent term (years) 4.11 - 4.94 Risk-free rate 4.06 - 4.16 % Dividend yield 0.00 % The fixed payment arrangements are recognized at their amortized cost basis using market appropriate discount rates and are accreted up to their ultimate face value over time.

Commitments and Contingencies

Commitments and Contingencies	3 Months Ended
Commitments and Contingencies	Sep. 30, 2022
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	13. Commitments and Contingencies Pediatric Portfolio Fixed Payments and Product Milestone The Company has two fixed, periodic payment obligations to an investor (the “Fixed Obligation”). Under the first fixed obligation, the Company was to pay monthly payment of $0.1 million beginning November 1, 2019 through January 2021, with a balloon payment of $15.0 million that was to be due in January 2021 (“Balloon Payment Obligation”). A second fixed obligation requires the Company pay a minimum of $0.1 monthly through February 2026, except for $0.2 paid in January 2020. On May 29, 2020, the Company entered into an Early Payment Agreement and Escrow Instruction (the “Early Payment Agreement”) pursuant to which the Company agreed to pay $15.0 million to the investor in satisfaction of the Balloon Payment Obligation. The parties to the Early Payment Agreement acknowledged and agreed that the remaining fixed payments other than the Balloon Payment Obligation remained due and payable pursuant to the terms of the Agreement, and that nothing in the Early Payment Agreement alters, amends, or waives any provisions or obligations in the Waiver or the Investor agreement other than as expressly set forth therein. The first fixed obligation was fully paid as of January 2021. On June 21, 2021, the Company entered into a Waiver, Release and Consent pursuant to which the Company paid $2.8 million to the investor in satisfaction of the second fixed obligation. The Company agreed to pay the remaining fixed obligation of $3.0 million in six equal quarterly payments of $0.5 million over the six quarters commencing September 30, 2021. In addition, the Company acquired a Supply and Distribution Agreement with Tris (the “Karbinal Agreement”), under which the Company is granted the exclusive right to distribute and sell the product in the United States. The initial term of the Karbinal Agreement was 20 years. The Company will pay Tris a royalty equal to 23.5% of net sales. The Karbinal Agreement also contains minimum unit sales commitments, which is based on a commercial year that spans from August 1 through July 31, of 70,000 units annually through 2025. The Company is required to pay Tris a royalty make whole payment of $30 for each unit under the 70,000-unit annual minimum sales commitment through 2025. The Karbinal Agreement make-whole payment is capped at $2.1 million each year. The annual payment is due in August of each year. The Karbinal Agreement also has multiple commercial milestone obligations that aggregate up to $3.0 million based on cumulative net sales, the first of which is triggered at $40.0 million of net revenues. Product Contingent Liability In February 2015, Innovus acquired Novalere, which included the rights associated with distributing FlutiCare. As part of the acquisition, Innovus is obligated to make five additional payments of $0.5 Pursuant to the UIRD Agreement, Innovus will pay to UIRD a total milestone payment of $50,000 every other year beginning on July 1, 2021 for a total payment of $0.2 million. The discounted value as of September 30, 2022, is approximately $0.1 million. Rumpus Earn Out Payments On April 12, 2021, the Company acquired substantially all of the assets of Rumpus, pursuant to which the Company acquired certain rights and other assets, including key commercial global licenses with Denovo Biopharma LLC (“Denovo”) and Johns Hopkins University (“JHU”), relating to AR101. Upon the achievement of certain regulatory and commercial milestones, up to $67.5 million in earn-out payments, which are payable in cash or shares of common stock, generally at the Company’s option, are payable to Rumpus. Under the license agreement with Denovo, the Company assumed the responsibility for paying annual maintenance fees of $25,000, a license option fee of $0.6 million payable in April 2022, and upon the achievement of certain regulatory and commercial milestones, up to $101.7 million, and escalating royalties based on net product sales ranging in percentage from the low teens to the high teens. Finally, under the license agreement with Johns Hopkins, the Company assumed the responsibility for paying minimum annual royalties escalating from $5,000 to $20,000 beginning in calendar year 2022, royalties of 3.0% of net product sales, and upon the achievement of certain regulatory and commercial milestones, up to $1.6 million.

Capital Structure

Capital Structure	3 Months Ended
Capital Structure	Sep. 30, 2022
Equity [Abstract]
Capital Structure	14. Capital Structure The Company has 200 million shares of common stock authorized with a par value of $0.0001 per share and 50 million shares of preferred stock authorized with a par value of $0.0001 per share. As of September 30, 2022 and June 30, 2022, the Company had 3,121,471 and 1,928,941 common shares outstanding, respectively, and zero preferred shares outstanding, respectively. Included in the common stock outstanding are 73,164 shares of unvested restricted stock issued to executives, directors and employees. On June 8, 2020, the Company filed a shelf registration statement on Form S-3, which was declared effective by the SEC on June 17, 2020. This shelf registration statement covered the offering, issuance and sale by the Company of up to an aggregate of $100.0 million of its common stock, preferred stock, debt securities, warrants, rights and units (the “2020 Shelf”). As of September 30, 2022, approximately $43.0 million remains available under the 2020 Shelf. On June 4, 2021, the Company entered into a sales agreement with a sales agent, to provide for the offering, issuance and sale by the Company of up to $30.0 million of its common stock from time to time in “at-the-market” offerings under the 2020 Shelf (the “ATM Sales Agreement”). During the quarter ended September 30, 2022, the Company issued an additional 31,407 shares of common stock under the ATM Sales Agreement, with total net proceeds of approximately $0.4 million. As of September 30, 2022, approximately $11.8 million of the Company’s common stock remained available to be sold pursuant to the ATM Sales Agreement. On September 28, 2021, the Company filed a shelf registration statement on Form S-3, which was declared effective by the SEC on October 7, 2021. This shelf registration statement covered the offering, issuance and sale by the Company of up to an aggregate of $100.0 million of its common stock, preferred stock, debt securities, warrants, rights and units (the “2021 Shelf”). As of September 30, 2022, approximately $82.4 million remained available under the 2021 Shelf. On August 11, 2022, the Company closed on an underwritten public offering (the “August 2022 Offering”), pursuant to which we sold an aggregate of (i) 1,075,290 shares of its common stock, (ii) and, in lieu of common stock to certain investors that so chose, pre-funded warrants (the “Pre-Funded Warrants”) to purchase 87,500 shares of its common stock, and (iii) accompanying warrants (the "Common Warrants") to purchase 1,265,547 shares of its common stock. The shares of common stock and the Pre-Funded Warrants were each sold in combination with corresponding Common Warrants, with one Common Warrant to purchase one share of common stock for each share of common stock or each Pre-Funded Warrant sold. The combined public offering price for each share of common stock and accompanying Common Warrant was $8.60, and the combined offering price for each Pre-Funded Warrant and accompanying Common Warrant was $8.58, which equated to the public offering price per share of the common stock and accompanying Common Warrant, less the $0.001 per share exercise price of each Pre-Funded Warrant. The Pre-Funded Warrants were exercised in full in August 2022. The Common Warrants have an exercise price of $8.60 per share of common stock and are exercisable for a period of five years from issuance. The Company raised $10.0 million in gross proceeds through the August 2022 Offering before underwriting fees and other expenses of $0.9 million. The Pre-Funded and Common Warrants have a combined fair value of approximately $6.0 million at issuance and are classified as derivative warrant liabilities in the Company’s financial statements. (See Note 16 – Warrants).

Equity Incentive Plans

Equity Incentive Plans	3 Months Ended
Equity Incentive Plans	Sep. 30, 2022
Share-Based Payment Arrangement [Abstract]
Equity Incentive Plans	15. Equity Incentive Plans Aytu 2015 Plan. On June 1, 2015, the Company’s stockholders approved the Aytu BioPharma 2015 Stock Option and Incentive Plan (the “Aytu 2015 Plan”), which, as amended in July 2017, provides for the award of stock options, stock appreciation rights, restricted stock and other equity awards for up to an aggregate of 150,000 shares of common stock. The shares of common stock underlying any awards that are forfeited, canceled, reacquired by Aytu prior to vesting, satisfied without any issuance of stock, expire or are otherwise terminated (other than by exercise) under the 2015 Plan will be added back to the shares of common stock available for issuance under the Aytu 2015 Plan. On February 13, 2020, the Company’s stockholders approved an increase to 250,000 total shares of common stock in the Aytu 2015 Plan. Stock options granted under this plan have contractual terms of 10 years from the grant date and a vesting period ranging from 3 to 4 years . The restricted stock awards have a vesting period ranging from 4 to 10 years , whereas the restricted stock units have a vesting period 4 years . As of September 30, 2022, the Company had 120,876 shares that are available for grant under the Aytu 2015 Plan. Neos 2015 Plan. Stock Options Stock option activity is as follows: Weighted Average Weighted Remaining Number of Average Contractual Options Exercise Price Life in Years Outstanding June 30, 2022 3,899 $ 209.70 7.77 Forfeited/Cancelled (74) 126.84 Expired (26) 157.84 Outstanding at September 30, 2022 3,799 $ 211.67 7.44 Exercisable at September 30, 2022 2,666 $ 231.99 7.41 As of September 30, 2022, there was $0.1 million total unrecognized compensation costs related to non-vested stock options granted under the Company’s equity incentive plans. The unrecognized compensation cost is expected to be recognized over a weighted average period of 1.4 years. Restricted Stock Restricted stock activity under the Aytu 2015 Plan is as follows: Weighted Average Grant Number of Date Fair Shares Value Unvested at June 30, 2022 80,373 $ 148.91 Granted 325 13.40 Vested (10,545) 115.60 Forfeited/Cancelled (1,993) 149.48 Unvested at September 30, 2022 68,160 $ 153.40 As of September 30, 2022, there was $8.2 million total unrecognized compensation costs related to non-vested restricted stock granted under the Company’s equity incentive plan. The unrecognized compensation cost is expected to be recognized over a weighted average period of 2.5 years. The Company previously issued 4 shares of restricted stock outside the Aytu 2015 Plan, which vest in July 2026. On January 17, 2022, the Company granted 5,000 shares of restricted stock to team outside of the Aytu 2015 Plan. As of September 30, 2022, there was total Restricted Stock Units RSUs activity is as follows: Weighted Average Grant Number of Date Fair Shares Value Unvested at June 30, 2022 8,500 $ 25.88 Granted — — Vested — — Forfeited — — Unvested at September 30, 2022 8,500 $ 25.88 As of September 30, 2022, there was $0.2 million total unrecognized compensation costs related to non-vested RSUs granted under the Company’s equity incentive plans. The unrecognized compensation cost is expected to be recognized over a weighted average period of 2.37 years. Stock-based compensation expense related to the fair value of stock options and restricted stock and RSUs was included in the statements of operations as set forth in the below table: Three Months Ended September 30, 2022 2021 (in thousands) Cost of sales $ 5 $ 9 Research and development 9 319 Selling and marketing 3 9 General and Administrative 1,160 1,182 Total stock-based compensation expense $ 1,177 $ 1,519

Warrants

Warrants	3 Months Ended
Warrants	Sep. 30, 2022
Warrants and Rights Note Disclosure [Abstract]
Warrants	16. Warrants Liability Classified Warrants On March 7, 2022, the Company closed on an underwritten public offering utilizing the 2021 Shelf, pursuant to which, the Company sold, (i) 151,500 shares of the Company’s common stock, (ii) prefunded warrants (the “Pre-Funded Warrants”) to purchase up to 151,500 shares of common stock, and (iii) common stock purchase warrants (the “Common Warrants”) to purchase up to 333,300 shares of common stock (the “March 2022 Offering”). The shares of common stock and the Pre-Funded Warrants were each sold in combination with corresponding Common Warrants, with one Common Warrant to purchase 1.1 shares of common stock for each share of common stock or each Pre-Funded Warrant sold. The Pre-Funded Warrants have an exercise price of $0.002 per share of common stock and were exercised in full in April 2022. The Common Warrants have an exercise price of $26.00 per share of common stock and are exercisable six months On August 11, 2022, the Company closed on the August 2022 Offering, pursuant to which, the Company issued Pre-Funded Warrants to purchase 87,500 shares of its common stock and Common Warrants to purchase 1,265,547 shares of its common stock. The shares of common stock and the Pre-Funded Warrants were each sold in combination with corresponding Common Warrants, which one Common Warrant to purchase one share of common stock for each share of common stock or each Pre-Funded Warrant sold. The Pre-Funded Warrants have an exercise price of $0.02 per share of common stock and were exercised in full in August 2022. The Common Warrants have an exercise price of $8.60 per share of common stock and are exercisable for a period of five years from issuance. The Common Warrants provide that if there occurs any a stock split, stock dividend stock recapitalization, or similar event (a “Stock Combination Event”), then the warrant exercise price will be adjusted to the greater of the quotient determined by dividing (x) the sum of the VWAP of the Common Stock for each of the five lowest trading days during the 20 consecutive trading day period ending immediately preceding the 16th trading day after such Stock Combination Event, divided by (y) five; or $2.32 and the number of shares of common stock to be issued would be adjusted proportionately as set forth in the agreement limited to a maximum of 2,325,581 shares. The Common Warrants also provide that in the event the Company were to engage in an equity offering at a common stock price lower than the warrant exercise price prior to the second anniversary of a Stock Combination Event, the exercise price would be adjusted to the greater of the effective price of such equity offering or $2.32 (see Note 14 – Capital Structure). The outstanding Common Warrants are classified as derivative warrant liabilities in the condensed consolidated balance sheets and are marked to market at each reporting period (see Note 12 – Fair Value Considerations) On January 26, 2022, as consideration for entering into the Avenue Capital Agreement, the Company issued Avenue Capital Warrants to the Avenue Capital Lenders to purchase 43,388 shares of common stock at an exercise price of $24.20 per share, subject to adjustment. The Avenue Capital Warrants were immediately exercisable and expire on January 31, 2027. A summary of warrants is as follows: Weighted Average Weighted Remaining Number of Average Contractual Warrants Exercise Price Life in Years Outstanding June 30, 2022 433,174 $ 92.30 4.73 Warrants issued 1,353,047 3.30 5.00 Warrants exercised (87,500) 0.02 5.00 Outstanding September 30, 2022 1,698,721 $ 31.00 4.76

Net Loss Per Common Share

Net Loss Per Common Share	3 Months Ended
Net Loss Per Common Share	Sep. 30, 2022
Net Loss Per Common Share
Net Loss Per Common Share	17. Net Loss per Common Share Basic income (loss) per common share is calculated by dividing the net income (loss) available to the common shareholders by the weighted average number of common shares outstanding during that period. Diluted net loss per share reflects the potential of securities that could share in the net loss of the Company. The following table sets-forth securities that are considered anti-dilutive, and therefore excluded from the calculation of diluted earnings per share. September 30, 2022 2021 Warrants to purchase common stock - liability classified 1,642,235 1,205 Warrant to purchase common stock - equity classified 56,486 58,022 Employee stock options 3,799 4,793 Employee unvested restricted stock 73,164 105,283 Employee unvested restricted stock units 8,500 3,858 Total 1,784,184 173,161

License Agreements

License Agreements	3 Months Ended
License Agreements	Sep. 30, 2022
License Agreement [Abstract]
Licensing Agreements	18. License Agreements Healight In April 2020, the Company entered into a licensing agreement with Cedars-Sinai Medical Center to secure worldwide rights to various potential esophageal and nasopharyngeal uses of Healight, an investigational medical device platform technology. The agreement with Cedars-Sinai grants the Company a license to all patent and development related technology rights for the intra-corporeal therapeutic use of ultraviolet light in the field of endotracheal and nasopharyngeal applications. The term of the agreement is on a country-by-country basis and will expire on the latest of the date upon which the last to expire valid claim shall expire, ten years after the first bona fide commercial sale of such licensed product in a country, or the expiration of any market exclusivity period granted by a regulatory agency. Pursuant to the terms of the agreement, the Company paid an initial $0.3 million license fee and approximately $0.1 million in earlier patent prosecution fees. NeuRx In October 2018, Neos entered into an Exclusive License Agreement (“NeuRx License”) with NeuRx Pharmaceuticals LLC (“NeuRx”), pursuant to which NeuRx granted Neos an exclusive, worldwide, royalty-bearing license to research, develop, manufacture, and commercialize certain pharmaceutical products containing NeuRx’s proprietary compound designated as NRX-101, referred to as NT0502. NT0502 is a new chemical entity that is being developed for the treatment of sialorrhea, which is excessive salivation or drooling. The Company may be required to make certain development and milestone payments and royalties based on annual net sales, as defined in the NeuRx License. Royalties are to be paid on a country-by-country and licensed product-by-licensed product basis, during the period of time beginning on the first commercial sale of such licensed product in such country and continuing until the later of: (i) the expiration of the last-to-expire valid claim in any licensed patent in such country that covers such licensed product in such country; and/or (ii) expiration of regulatory exclusivity of such licensed product in such country. Teva On December 21, 2018, Neos and Teva Pharmaceuticals USA, Inc. (“Teva”) entered into an agreement granting Teva a non-exclusive license to certain patents owned by Neos by which Teva has the right to manufacture and market its generic version of Cotempla XR-ODT under an Abbreviated New Drug Application (“ANDA”) filed by Teva beginning on July 1, 2026, or earlier under certain circumstances. Actavis On October 17, 2017, Neos entered into an agreement granting Actavis a non-exclusive license to certain patents owned by Neos by which Actavis has the right to manufacture and market its generic version of Adzenys XR-ODT under its ANDA beginning on September 1, 2025, or earlier under certain circumstances. Shire In July 2014, Neos entered into a Settlement Agreement and an associated License Agreement (the “2014 License Agreement”) with Shire LLC (“Shire”) for a non-exclusive license to certain patents for certain activities with respect to Neos’ New Drug Application (the “NDA”) No. 204326 for an extended-release orally disintegrating amphetamine polistirex tablet. In accordance with the terms of the 2014 License Agreement, following the receipt of the approval from the FDA for Adzenys XR-ODT, Neos paid an up-front, non-refundable license fee of an amount less than $1.0 million in February 2016. Neos is paying a single digit royalty on net sales of Adzenys XR-ODT during the life of the patents. In March 2017, Neos entered into a License Agreement (the “2017 License Agreement”) with Shire, pursuant to which Shire granted Neos a non-exclusive license to certain patents owned by Shire for certain activities with respect to Neos’ NDA No. 204325 for an extended-release amphetamine oral suspension. In accordance with the terms of the 2017 License Agreement, following the receipt of the approval from the FDA for Adzenys ER, Neos paid an up-front, non-refundable license fee of an amount less than $1.0 million in October 2017. Neos was paying a single digit royalty on net sales of Adzenys ER during the life of the patents. Adzenys ER was discontinued as of September 30, 2021. The royalties are recorded as cost of goods sold in the same period as the net sales upon which they are calculated. Additionally, each of the 2014 and 2017 License Agreements contains a covenant from Shire not to file a patent infringement suit against Neos alleging that Adzenys XR-ODT or Adzenys ER, respectively, infringes the Shire patents.

Segment Reporting

Segment Reporting	3 Months Ended
Segment Reporting	Sep. 30, 2022
Segment Reporting [Abstract]
Segment Reporting	19. Segment Reporting The Company’s chief operating decision maker (“CODM”), who is the Company’s Chief Executive Officer, allocates resources and assesses performance based on financial information of the Company. The CODM reviews financial information presented for each reportable segment for purposes of making operating decisions and assessing financial performance. The Company manages and aggregates its operational and financial information in accordance with two reportable segments: Rx and Consumer Health. The Rx segment consists of the Company’s prescription products. The Consumer Health segment contains the Company’s consumer healthcare products. Select financial information for these segments is as follows: Three Months Ended September 30, 2022 2021 (In thousands) Consolidated revenue: Rx Segment $ 18,652 $ 13,883 Consumer Health Segment 9,003 8,014 Consolidated revenue $ 27,655 $ 21,897 Consolidated net loss: Rx Segment $ 126 $ (26,457) Consumer Health Segment (827) (1,394) Consolidated net loss $ (701) $ (27,851) September 30, June 30, 2022 2022 (In thousands) Total assets: Rx Segment $ 134,067 $ 121,377 Consumer Health Segment 15,933 16,246 Consolidated assets $ 150,000 $ 137,623

Subsequent Events

Subsequent Events	3 Months Ended
Subsequent Events	Sep. 30, 2022
Subsequent Events [Abstract]
Subsequent Events	20. Subsequent Events On October 25, 2022, the Company entered into an agreement with Avenue Venture Opportunities Fund, L.P (“Avenue”) to extend the interest-only period of its existing senior secure loan facility held with Avenue. The amendment to the original loan agreement, which was executed in January 2022, extends the interest-only period to January of 2024. In exchange for this extension of the interest-only period, the Company and Avenue agreed to reset the exercise price of the warrants issued in conjunction with the original loan agreement to

Significant Accounting Polici_2

Significant Accounting Policies (Policies)	3 Months Ended
Significant Accounting Policies (Policies)	Sep. 30, 2022
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation. Also see Note 2 – Previously Reported Financial Statements the immaterial correction of an error in the condensed consolidated balance sheet and the condensed consolidated statement of stockholders’ equity for as of June 30, 2022.
Prior Period Reclassification	Prior Period Reclassification.
Use of Estimates	Use of Estimates Management uses estimates and assumptions relating to reporting amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements and the reported amount of revenues and expenses during the reporting period. In the accompanying condensed consolidated financial statements, estimates are used for, but not limited to, stock-based compensation, revenue recognition, allowance for doubtful accounts, determination of variable consideration for accruals of chargebacks, administrative fees and rebates, government rebates, returns and other allowances, allowance for inventory obsolescence, valuation of financial instruments and intangible assets, accruals for contingent liabilities, fair value of long-lived assets, the value of goodwill, income tax provision, deferred taxes and valuation allowance, determination of right-of-use assets and lease liabilities, purchase price allocations, the depreciable lives of long-lived assets, classification of warrants equity versus liability, and valuation of derivative warrant liability. Because of the uncertainties inherent in such estimates, actual results may differ from those estimates. Management periodically evaluates estimates used in the preparation of the financial statements for reasonableness.
Previously Reported Financial Statements	Previously Reported Financial Statements The classification of certain of the Company’s warrants were previously recorded as equity. These warrants according to GAAP should have been classified as derivative warrant liabilities at fair value and marked to market at each reporting period, with changes in fair value recorded in earnings. The affected filing periods are the quarterly unaudited financial statements as of March 31, 2022 and September 30, 2022, and the audited financial statements as of June 30, 2022. SEC Staff Accounting Bulletin No. 99, “Materiality,” and FASB, Statement of Financial Accounting Concepts No. 2 “Qualitative Characteristics of Accounting Information” indicate that quantifying and aggregating errors is only the beginning of an analysis of materiality and that both quantitative and qualitative factors must be considered in determining whether individual errors are material. The Company evaluated the corrections and have determined that the impact was not material for the periods ended March 31, 2022 and June 30, 2022, but is material for the period ended September 30, 2022. The assessment resulted in the amendment of the previously reported financial statements reported in the Company’s first quarter of 2023 Form 10-Q. The balance sheet as at June 30, 2022 included in this amended Form 10-Q/A has been adjusted for the immaterial correction of this error. In addition, financial statements for the period ended March 31, 2022 and for the fiscal year ended June 30, 2022 will be adjusted at the time of their reissuance. The condensed consolidated financial statements and certain of the notes to the condensed consolidated financial statements as of and for the three months ended September 30, 2022 have been restated to reflect the corrections. The impact of the restatement for the period ended September 30, 2022 is shown in the tables below and did not change the Company’s reported total assets, cash and cash equivalents, operating expenses, operating losses or cash flows from operations. As of September 30, 2022 As Previously Reported Adjustment As Restated (in thousands) Derivative warrant liability $ — $ 5,558 $ 5,558 Total liabilities 96,094 5,558 101,652 Additional paid-in capital 345,253 (9,126) 336,127 Accumulated deficit (291,353) 3,574 (287,779) Total stockholders’ equity 53,906 (5,558) 48,348 Three Months Ended September 30, 2022 As Previously Reported Adjustment As Restated (in thousands) Statement of Operation data Gain on derivative warrant liabilities $ — $ 2,191 $ 2,191 Total other (expense) income (1,228) 2,180 952 Loss before income tax (2,881) 2,180 (701) Net loss (2,881) 2,180 (701) Basic and diluted net loss per common share (1.14) 0.86 (0.28) Statement of Cash Flow data Net loss $ (2,881) $ 2,180 $ (701) Gain on derivative warrant liabilities — 2,191 2,191 Net loss by segment Rx Segment $ (2,054) $ 2,180 $ 126 Consumer Health Segment (827) — (827) Consolidated net loss (2,881) 2,180 (701) The condensed consolidated balance sheet and the condensed consolidated statement of stockholders’ equity as of June 30, 2022 have been adjusted for comparative purposes. The impact of the immaterial correction of an error for as of June 30, 2022 is shown in the table below. As of June 30, 2022 As Previously Reported Adjustment As Adjusted (in thousands) Derivative warrant liability $ — $ 1,796 $ 1,796 Total liabilities 91,531 1,784 93,315 Additional paid-in capital 334,560 (3,174) 331,386 Accumulated deficit (288,472) 1,394 (287,078) Total stockholders’ equity 46,092 (1,784) 44,308
Warrants	Warrants The Company accounts for warrants as either equity-classified or liability-classified instruments based on an assessment of the warrant’s specific terms and applicable authoritative guidance in Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) 480, Distinguishing Liabilities from Equity (“ASC 480”) and ASC 815, Derivatives and Hedging (“ASC 815”). The assessment considers whether the warrants are freestanding financial instruments pursuant to ASC 480, meet the definition of a liability pursuant to ASC 480, and whether the warrants meet all of the requirements for equity classification under ASC 815, including whether the warrants are indexed to the Company’s own common shares and whether the warrant holders could potentially require “net cash settlement” in a circumstance outside of the Company’s control, among other conditions for equity classification. This assessment, which requires the use of professional judgment, is conducted at the time of warrant issuance and as of each subsequent quarterly period end date while the warrants are outstanding. Liability and equity classified warrants are valued using either a Black-Scholes option
Income Taxes	Income Taxes The Company calculates its quarterly income tax provision based on estimated annual effective tax rates applied to ordinary income (or loss) and other known items computed and recognized when they occur. There have been no changes in tax law affecting the tax provision during the three months ended September 30, 2022. An ownership change (generally a 50% change in equity ownership over a three-year period) could limit the Company’s ability to offset, post-change, U.S. federal taxable income. Section 382 of the Code imposes an annual limitation on the amount of post-ownership change taxable income a corporation may offset with pre-ownership change net operating loss carryforwards and certain recognized built-in losses. The Company believes that previous acquisitions, financing transactions, and equity ownership changes in the past five years may have caused an ownership change results in a limitation of its ability to use the pre-acquisition net operating loss carryovers. The ownership change scenario could result in increased future tax liability. The company is in the process of analyzing the impact of any possible ownership change the result of which may be a change to the Company’s net deferred tax asset or liability position.
Impairment of Other Intangibles Assets	Impairment of Other Intangibles Assets Acquired in-process research and development (“IPR&D) is an intangible asset classified as an indefinite-lived asset until the completion or abandonment of the associated research and development (“R&D”) effort. In periods after the acquired IPR&D, the Company may (1) continue internal R&D efforts associated with the acquired assets or collaborate with another party in R&D efforts; (2) dispose of the assets through sale; (3) outlicense the assets; (4) decide to temporarily postpone further development; or (5) abandon R&D efforts. IPR&D asset may be subject to different subsequent accounting treatment depending on the course of action chosen by the Company with respect to the asset. If the Company changes strategies related to the IPR&D the asset could potentially be impaired.
Recently Adopted Accounting Pronouncements and Recent Accounting Pronouncements Not Yet Adopted	Recent Adopted Accounting Pronouncements Reference Rate Reform. , Reference Rate Reform (Topic 848): “Facilitation of the Effects of Reference Rate Reform on Financial Reporting” Earnings Per Share. In May 2021, the FASB issued ASU 2021-04, “ Earnings Per Share (Topic 260), Debt – Modifications and Extinguishments (Subtopic 470-50), Compensation – Stock Compensation (Topic 718), and Derivatives and Hedging – Contracts in Entity’s Own Equity (Subtopic 815-40): Issuer’s Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options ”. The amendments in ASU 2021-04 provide guidance to clarify and reduce diversity in an issuer’s accounting for modifications or exchanges of freestanding equity-classified written call options (for example, warrants) that remain equity classified after modification or exchange. ASU 2021-04 is effective for all entities for fiscal years beginning after December 15, 2021, and interim periods within those fiscal years, with early adoption permitted. The adoption of ASU 2021-04 and related updates did not have a material impact on its condensed consolidated financial statements. Recent Accounting Pronouncements Not Yet Adopted Debt—Debt with Conversion and Other Options. Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging— Contracts in Entity’s Own Equity (Subtopic 815-40)— “Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity” smaller reporting companies, as defined by the Securities and Exchange Commission (”SEC”), for the fiscal years beginning after December 15, 2023, including interim periods within those fiscal years. Early adoption is permitted through a modified retrospective or full retrospective method. The Company will adopt the guidance on July 1, 2023 and does not expect the adoption of the standard to have any material impact on the Company’s condensed consolidated financial position and results of operations. Financial Instruments Credit Losses. ASU 2016-13, “Financial Instruments – Credit Losses” For a complete set of the Company’s significant accounting policies, refer to our Annual Report on Form 10-K for the fiscal year ended June 30, 2022. There have been no significant changes to the Company’s significant accounting policies during the three months ended September 30, 2022.

Significant Accounting Polici_3

Significant Accounting Policies (Tables)	3 Months Ended
Significant Accounting Policies (Tables)	Sep. 30, 2022
Accounting Policies [Abstract]
Schedule of the impact of the immaterial correction of an error	As of September 30, 2022 As Previously Reported Adjustment As Restated (in thousands) Derivative warrant liability $ — $ 5,558 $ 5,558 Total liabilities 96,094 5,558 101,652 Additional paid-in capital 345,253 (9,126) 336,127 Accumulated deficit (291,353) 3,574 (287,779) Total stockholders’ equity 53,906 (5,558) 48,348 Three Months Ended September 30, 2022 As Previously Reported Adjustment As Restated (in thousands) Statement of Operation data Gain on derivative warrant liabilities $ — $ 2,191 $ 2,191 Total other (expense) income (1,228) 2,180 952 Loss before income tax (2,881) 2,180 (701) Net loss (2,881) 2,180 (701) Basic and diluted net loss per common share (1.14) 0.86 (0.28) Statement of Cash Flow data Net loss $ (2,881) $ 2,180 $ (701) Gain on derivative warrant liabilities — 2,191 2,191 Net loss by segment Rx Segment $ (2,054) $ 2,180 $ 126 Consumer Health Segment (827) — (827) Consolidated net loss (2,881) 2,180 (701) As of June 30, 2022 As Previously Reported Adjustment As Adjusted (in thousands) Derivative warrant liability $ — $ 1,796 $ 1,796 Total liabilities 91,531 1,784 93,315 Additional paid-in capital 334,560 (3,174) 331,386 Accumulated deficit (288,472) 1,394 (287,078) Total stockholders’ equity 46,092 (1,784) 44,308

Revenues from Contracts with _2

Revenues from Contracts with Customers (Tables)	3 Months Ended
Revenues from Contracts with Customers (Tables)	Sep. 30, 2022
Revenue from Contract with Customer [Abstract]
Schedule of disaggregation of revenue	Three Months Ended September 30, 2022 2021 ADHD Portfolio $ 11,585 $ 9,327 Pediatric Portfolio 6,558 3,798 Consumer Health Portfolio 9,003 8,014 Other 509 758 Consolidated revenue $ 27,655 $ 21,897
Schedule of product revenues by geographic location	Three Months Ended September 30, 2022 2021 (In thousands) U.S. $ 27,476 $ 21,106 International 179 791 Total net revenue $ 27,655 $ 21,897

Inventories (Tables)

Inventories (Tables)	3 Months Ended
Inventories (Tables)	Sep. 30, 2022
Inventory Disclosure [Abstract]
Schedule of Inventory balances	September 30, June 30, 2022 2022 (In thousands) Raw materials $ 2,113 $ 1,814 Work in process 2,374 1,838 Finished goods 8,384 7,197 Inventory, net $ 12,871 $ 10,849

Property and Equipment (Tables)

Property and Equipment (Tables)	3 Months Ended
Property and Equipment (Tables)	Sep. 30, 2022
Property, Plant and Equipment [Abstract]
Schedule of property and equipment	September 30, June 30, 2022 2022 (In thousands) Manufacturing equipment $ 2,449 $ 2,487 Leasehold improvements 999 999 Office equipment, furniture and other 1,128 1,128 Lab equipment 832 832 Property and equipment, gross 5,408 5,446 Less accumulated depreciation and amortization (2,736) (2,421) Property and equipment, net $ 2,672 $ 3,025

Leases (Tables)

Leases (Tables)	3 Months Ended
Leases (Tables)	Sep. 30, 2022
Leases [Abstract]
Schedule of components of lease expenses	Three Months Ended September 30, 2022 2021 Statement of Operations Classification (In thousands) Lease cost: Operating lease cost $ 222 $ 296 Operating expenses Short-term lease cost 160 39 Operating expenses Finance lease cost: Amortization of leased assets 18 18 Cost of sales Interest on lease liabilities 3 4 Other (expense), net Total net lease cost $ 403 $ 357
Schedule of balance sheet information related to leases	September 30, June 30, Balance Sheet Classification 2022 2022 (In thousands) Assets: Operating lease assets $ 2,976 $ 3,271 Operating lease right-of-use asset Finance lease assets 238 256 Property and equipment, net Total leased assets $ 3,214 $ 3,527 Liabilities: Current: Operating leases $ 1,252 $ 1,227 Other current liabilities Finance leases 92 96 Current portion of debt Non-current Operating leases 1,768 2,090 Other non-current liabilities Finance leases 62 84 Debt, net of current portion Total lease liabilities $ 3,174 $ 3,497
Schedule of remaining lease term and discount rate	September 30, June 30, 2022 2022 Weighted-Average Remaining Lease Term (years) Operating lease assets 2.39 2.63 Finance lease assets 1.48 1.73 Weighted-Average Discount Rate Operating lease assets 7.54 % 7.48 % Finance lease assets 6.43 % 6.43 %
Schedule of supplemental cash flow information related to leases	Three Months Ended September 30, 2022 2021 (In thousands) Cash flow classification of lease payments: Operating cash flows from operating leases $ 357 $ 282 Operating cash flows from finance leases $ 3 $ 4 Financing cash flows from finance leases $ 27 $ 25
Schedule of maturities of future minimum lease payments, operating leases	Operating Finance (In thousands) 2023 (remaining 9 months) $ 1,079 $ 75 2024 1,379 87 2025 749 — 2026 90 — 2027 46 — Total lease payments 3,343 162 Less: Imputed interest (323) (8) Lease liabilities $ 3,020 $ 154
Schedule of maturities of future minimum lease payments, finance leases	Operating Finance (In thousands) 2023 (remaining 9 months) $ 1,079 $ 75 2024 1,379 87 2025 749 — 2026 90 — 2027 46 — Total lease payments 3,343 162 Less: Imputed interest (323) (8) Lease liabilities $ 3,020 $ 154

Goodwill and Other Intangible_2

Goodwill and Other Intangible Assets (Tables)	3 Months Ended
Goodwill and Other Intangible Assets (Tables)	Sep. 30, 2022
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of finite lived intangible assets	September 30, 2022 Weighted- Gross Net Average Carrying Accumulated Carrying Remaining Amount Amortization Impairment Amount Life (in years) (In thousands) Definite-lived intangibles: Acquired product technology rights 45,400 (8,471) (3,224) 33,705 12.04 Acquired technology right 30,200 (2,722) — 27,478 15.50 Acquired product distribution rights 11,354 (3,857) (2,172) 5,325 7.35 86,954 (15,050) (5,396) 66,508 13.10 Indefinite-lived intangibles: Acquired in-process R&D 2,600 — — 2,600 Indefinite-lived 2,600 — — 2,600 Total $ 89,554 $ (15,050) $ (5,396) $ 69,108 13.10 June 30, 2022 Weighted- Gross Net Average Carrying Accumulated Carrying Remaining Amount Amortization Impairment Amount Life (in years) (In thousands) Definite-lived intangibles: Acquired product technology rights $ 45,400 $ (7,667) $ (3,224) $ 34,509 12.33 Acquired technology right 30,200 (2,278) — 27,922 15.75 Acquired product distribution rights 11,354 (3,581) (2,172) 5,601 7.60 Other intangible assets 4,666 (3,004) (1,662) — — 91,620 (16,530) (7,058) 68,032 13.35 Indefinite-lived intangibles: Acquired in-process R&D 2,600 — — 2,600 Indefinite-lived 2,600 — — 2,600 Total $ 94,220 $ (16,530) $ (7,058) $ 70,632 13.35
Schedule of Indefinite lived intangible assets	September 30, 2022 Weighted- Gross Net Average Carrying Accumulated Carrying Remaining Amount Amortization Impairment Amount Life (in years) (In thousands) Definite-lived intangibles: Acquired product technology rights 45,400 (8,471) (3,224) 33,705 12.04 Acquired technology right 30,200 (2,722) — 27,478 15.50 Acquired product distribution rights 11,354 (3,857) (2,172) 5,325 7.35 86,954 (15,050) (5,396) 66,508 13.10 Indefinite-lived intangibles: Acquired in-process R&D 2,600 — — 2,600 Indefinite-lived 2,600 — — 2,600 Total $ 89,554 $ (15,050) $ (5,396) $ 69,108 13.10 June 30, 2022 Weighted- Gross Net Average Carrying Accumulated Carrying Remaining Amount Amortization Impairment Amount Life (in years) (In thousands) Definite-lived intangibles: Acquired product technology rights $ 45,400 $ (7,667) $ (3,224) $ 34,509 12.33 Acquired technology right 30,200 (2,278) — 27,922 15.75 Acquired product distribution rights 11,354 (3,581) (2,172) 5,601 7.60 Other intangible assets 4,666 (3,004) (1,662) — — 91,620 (16,530) (7,058) 68,032 13.35 Indefinite-lived intangibles: Acquired in-process R&D 2,600 — — 2,600 Indefinite-lived 2,600 — — 2,600 Total $ 94,220 $ (16,530) $ (7,058) $ 70,632 13.35
Schedule of future amortization expense	September 30, (In thousands) 2023 (remaining 9 months) $ 4,563 2024 6,074 2025 5,934 2026 5,683 2027 5,652 2028 5,552 Thereafter 33,050 Total future amortization expense $ 66,508

Accrued Liabilities (Tables)

Accrued Liabilities (Tables)	3 Months Ended
Accrued Liabilities (Tables)	Sep. 30, 2022
Accrued Liabilities, Current [Abstract]
Schedule of Accrued liabilities	September 30, June 30, 2022 2022 (In thousands) Accrued savings offers $ 11,801 $ 12,711 Accrued program liabilities 8,080 9,468 Product return reserve 5,826 5,770 Accrued employee compensation 5,679 4,765 Accrued customer and product related fees 6,832 7,817 Other accrued liabilities 3,213 3,656 Total accrued liabilities $ 41,431 $ 44,187

Other Liabilities (Tables)

Other Liabilities (Tables)	3 Months Ended
Other Liabilities (Tables)	Sep. 30, 2022
Other Liabilities Disclosure [Abstract]
Schedule of other liabilities	September 30, June 30, 2022 2022 (In thousands) Fixed payment arrangements $ 12,472 $ 13,051 Contingent value rights 706 578 Contingent consideration 423 396 Operating lease liabilities 3,020 3,317 Other 803 815 Total other liabilities 17,424 18,157 Less: current portion (8,094) (5,359) Total other liabilities, noncurrent $ 9,330 $ 12,798

Long-term Debt (Tables)

Long-term Debt (Tables)	3 Months Ended
Long-term Debt (Tables)	Sep. 30, 2022
Long-term Debt
Schedule of long term debt	September 30, 2022 (In thousands) Long-term debt, due on January 26, 2025 $ 15,000 Long-term, final payment fee 638 Unamortized discount and issuance costs (1,306) Financing leases, maturing through May 2024 154 Total debt 14,485 Less: current portion (925) Non-current portion of debt $ 13,560
Schedule of future principal payments of long term debt	September 30, (In thousands) 2023 $ 92 2024 8,395 2025 7,304 Future principal payments 15,791 Less unamortized discount and issuance costs (1,306) Less current portion (925) Non-current portion of debt $ 13,560

Fair Value Considerations (Tabl

Fair Value Considerations (Tables)	3 Months Ended
Fair Value Considerations (Tables)	Sep. 30, 2022
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Schedule of fair value on a recurring basis	Fair Value Measurements at September 30, 2022 Fair Value at September 30, 2022 (Level 1) (Level 2) (Level 3) (In thousands) Assets: Cash and cash equivalents $ 23,811 $ 23,811 $ — $ — Total $ 23,811 $ 23,811 $ — $ — Liabilities: Contingent consideration $ 423 $ — $ — $ 423 CVR liability 706 — — 706 Derivative warrant liabilities (As Restated) 5,558 — — 5,558 Total $ 6,687 $ — $ — $ 6,687 Fair Value Measurements at June 30, 2022 Fair Value at June 30, 2022 (Level 1) (Level 2) (Level 3) (In thousands) Assets: Cash and cash equivalents $ 19,360 $ 19,360 $ — $ — Total $ 19,360 $ 19,360 $ — $ — Liabilities: Contingent consideration $ 396 $ — $ — $ 396 CVR liability 578 — — 578 Derivative warrant liabilities 1,796 — — 1,796 Total $ 2,770 $ — $ — $ 2,770
Schedule of changes in Level 3 inputs	CVR Contingent Derivative Fixed Payment Liability Consideration Warrant Liabilities Arrangement (In thousands) Balance as of June 30, 2022 $ 578 $ 396 $ 1,796 $ 13,051 Included in earnings 128 27 (2,191) 446 Purchases, issues, sales and settlements: Issues — — 5,953 — Settlements — — — (1,025) Balance as of September 30, 2022 $ 706 $ 423 $ 5,558 $ 12,472
Contingent Value Rights
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Schedule of significant assumptions used in valuation	September 30, 2022 Leveraged Beta 0.84 Market risk premium 6.22 % Risk-free interest rate 4.09 % Discount 21.50 % Company specific discount 10.00 %
Derivative Financial Instruments, Liabilities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Schedule of significant assumptions used in valuation	August 9, 2022 Expected volatility 89.89 % Equivalent term (years) 4.11 Risk-free rate 3.09 % Dividend yield 0.00 % September 30, 2022 Expected volatility 87.33 % Equivalent term (years) 4.11 - 4.94 Risk-free rate 4.06 - 4.16 % Dividend yield 0.00 %

Equity Incentive Plans (Tables)

Equity Incentive Plans (Tables)	3 Months Ended
Equity Incentive Plans (Tables)	Sep. 30, 2022
Share-Based Payment Arrangement [Abstract]
Stock option activity	Weighted Average Weighted Remaining Number of Average Contractual Options Exercise Price Life in Years Outstanding June 30, 2022 3,899 $ 209.70 7.77 Forfeited/Cancelled (74) 126.84 Expired (26) 157.84 Outstanding at September 30, 2022 3,799 $ 211.67 7.44 Exercisable at September 30, 2022 2,666 $ 231.99 7.41
Restricted stock activity	Weighted Average Grant Number of Date Fair Shares Value Unvested at June 30, 2022 80,373 $ 148.91 Granted 325 13.40 Vested (10,545) 115.60 Forfeited/Cancelled (1,993) 149.48 Unvested at September 30, 2022 68,160 $ 153.40
Restricted stock units activity	Weighted Average Grant Number of Date Fair Shares Value Unvested at June 30, 2022 8,500 $ 25.88 Granted — — Vested — — Forfeited — — Unvested at September 30, 2022 8,500 $ 25.88
Stock-based compensation expense	Three Months Ended September 30, 2022 2021 (in thousands) Cost of sales $ 5 $ 9 Research and development 9 319 Selling and marketing 3 9 General and Administrative 1,160 1,182 Total stock-based compensation expense $ 1,177 $ 1,519

Warrants (Tables)

Warrants (Tables)	3 Months Ended
Warrants (Tables)	Sep. 30, 2022
Warrants and Rights Note Disclosure [Abstract]
Summary of warrants	Weighted Average Weighted Remaining Number of Average Contractual Warrants Exercise Price Life in Years Outstanding June 30, 2022 433,174 $ 92.30 4.73 Warrants issued 1,353,047 3.30 5.00 Warrants exercised (87,500) 0.02 5.00 Outstanding September 30, 2022 1,698,721 $ 31.00 4.76

Net Loss Per Common Share (Tabl

Net Loss Per Common Share (Tables)	3 Months Ended
Net Loss Per Common Share (Tables)	Sep. 30, 2022
Net Loss Per Common Share
Antidilutive securities excluded from the computation of earnings per share	September 30, 2022 2021 Warrants to purchase common stock - liability classified 1,642,235 1,205 Warrant to purchase common stock - equity classified 56,486 58,022 Employee stock options 3,799 4,793 Employee unvested restricted stock 73,164 105,283 Employee unvested restricted stock units 8,500 3,858 Total 1,784,184 173,161

Segment Reporting (Tables)

Segment Reporting (Tables)	3 Months Ended
Segment Reporting (Tables)	Sep. 30, 2022
Segment Reporting [Abstract]
Schedule of segment financial information, consolidated revenue	Three Months Ended September 30, 2022 2021 (In thousands) Consolidated revenue: Rx Segment $ 18,652 $ 13,883 Consumer Health Segment 9,003 8,014 Consolidated revenue $ 27,655 $ 21,897 Consolidated net loss: Rx Segment $ 126 $ (26,457) Consumer Health Segment (827) (1,394) Consolidated net loss $ (701) $ (27,851)
Schedule of segment financial information, consolidated net loss	Three Months Ended September 30, 2022 2021 (In thousands) Consolidated revenue: Rx Segment $ 18,652 $ 13,883 Consumer Health Segment 9,003 8,014 Consolidated revenue $ 27,655 $ 21,897 Consolidated net loss: Rx Segment $ 126 $ (26,457) Consumer Health Segment (827) (1,394) Consolidated net loss $ (701) $ (27,851)
Schedule of segment financial information, total assets	September 30, June 30, 2022 2022 (In thousands) Total assets: Rx Segment $ 134,067 $ 121,377 Consumer Health Segment 15,933 16,246 Consolidated assets $ 150,000 $ 137,623

Nature of Business, Financial_2

Nature of Business, Financial Condition, Basis of Presentation - Segments (Details) - segment	3 Months Ended
	Sep. 30, 2022	Sep. 30, 2021
Segment Reporting, Disclosure of Entity's Reportable Segments [Abstract]
Number of reportable segments	2	2

Nature of Business, Financial_3

Nature of Business, Financial Condition, Basis of Presentation - Reverse Stock Split (Details)	Jan. 06, 2023
Subsequent Event
Class of Stock [Line Items]
Stock split, conversion ratio	20

Nature of Business, Financial_4

Nature of Business, Financial Condition, Basis of Presentation - Product Information (Details)	3 Months Ended
	Sep. 30, 2022 item product	Sep. 30, 2021 item
Consumer Health Portfolio \| Minimum
Disaggregation of Revenue [Line Items]
Number of products \| product	20
Rx
Disaggregation of Revenue [Line Items]
Number of product portfolios \| item	2	2

Nature of Business, Financial_5

Nature of Business, Financial Condition, Basis of Presentation - General Information (Details) - USD ($) $ in Thousands	3 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents [Abstract]
Cash, cash equivalents and restricted cash	$ 23,811	$ 40,560	$ 19,360	$ 49,901
Accounts Receivable, after Allowance for Credit Loss, Current [Abstract]
Accounts receivable, net	27,924		21,712
Net Income (Loss) Attributable to Parent [Abstract]
Net loss	(701)	(27,851)
Retained Earnings (Accumulated Deficit) [Abstract]
Accumulated deficit	(287,779)		$ (287,078)
Net Cash Provided by (Used in) Operating Activities [Abstract]
Cash used in operations	$ (9,148)	$ (3,791)

Nature of Business, Financial_6

Nature of Business, Financial Condition, Basis of Presentation - Stock Offerings (Details) - USD ($) $ in Thousands		3 Months Ended
	Aug. 11, 2022	Sep. 30, 2022	Sep. 30, 2021
Subsidiary, Sale of Stock [Line Items]
Proceeds from issuance of common stock and warrants, net of issuance costs		$ 10,416	$ 307
Shelf Registration Statement, 2021 Shelf, Underwritten Public Offering, August 2022
Subsidiary, Sale of Stock [Line Items]
Issuance of common stock (in shares)	1,075,290
Proceeds from issuance of common stock and warrants	$ 10,000
Proceeds from issuance of common stock and warrants, net of issuance costs	$ 9,100

Nature of Business, Financial_7

Nature of Business, Financial Condition, Basis of Presentation - Warrants (Details)	Aug. 11, 2022 shares
Warrants to Purchase Common Stock, Liability Classified, Pre-funded Warrants, August 2022
Class of Warrant or Right [Line Items]
Class of warrant or right, number of securities called by warrants or right (in shares)	87,500
Warrants to Purchase Common Stock, Liability Classified, Common Warrants, August 2022
Class of Warrant or Right [Line Items]
Class of warrant or right, number of securities called by warrants or right (in shares)	1,265,547

Nature of Business, Financial_8

Nature of Business, Financial Condition, Basis of Presentation - Going Concern (Details)	3 Months Ended
	Sep. 30, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Substantial Doubt about Going Concern, within One Year	true

Significant Accounting Polici_4

Significant Accounting Policies - Previously Reported Financial Statements - Balance Sheet and Statement of Stockholders' Equity (Details) - USD ($) $ in Thousands	Sep. 30, 2022	Jun. 30, 2022	Sep. 30, 2021	Jun. 30, 2021
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Derivative warrant liabilities	$ 5,558	$ 1,796
Total liabilities	101,652	93,315
Additional paid-in capital	336,127	331,386
Accumulated deficit	(287,779)	(287,078)
Total stockholders' equity	48,348	44,308	$ 111,500	$ 137,568
Previously Reported
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Total liabilities	96,094	91,531
Additional paid-in capital	345,253	334,560
Accumulated deficit	(291,353)	(288,472)
Total stockholders' equity	53,906	46,092
Revision of Prior Period, Error Correction, Adjustment
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Derivative warrant liabilities	5,558	1,796
Total liabilities	5,558	1,784
Additional paid-in capital	(9,126)	(3,174)
Accumulated deficit	3,574	1,394
Total stockholders' equity	$ (5,558)	$ (1,784)

Significant Accounting Polici_5

Significant Accounting Policies - Previously Reported Financial Statements - Statement of Operation (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended
	Sep. 30, 2022	Sep. 30, 2021
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Gain on derivative warrant liabilities	$ 2,191
Total other (expense) income	952	$ (259)
Loss before income tax	(701)	(27,958)
Net loss	$ (701)	$ (27,851)
Basic net loss per common share (in dollars per share)	$ (0.28)	$ (21.76)
Diluted net loss per common share (in dollars per share)	$ (0.28)	$ (21.76)
Previously Reported
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Total other (expense) income	$ (1,228)
Loss before income tax	(2,881)
Net loss	$ (2,881)
Basic net loss per common share (in dollars per share)	$ (1.14)
Diluted net loss per common share (in dollars per share)	$ (1.14)
Revision of Prior Period, Error Correction, Adjustment
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Gain on derivative warrant liabilities	$ 2,191
Total other (expense) income	2,180
Loss before income tax	2,180
Net loss	$ 2,180
Basic net loss per common share (in dollars per share)	$ 0.86
Diluted net loss per common share (in dollars per share)	$ 0.86

Significant Accounting Polici_6

Significant Accounting Policies - Previously Reported Financial Statements - Statement of Cash Flow (Details) - USD ($) $ in Thousands	3 Months Ended
	Sep. 30, 2022	Sep. 30, 2021
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Net loss	$ (701)	$ (27,851)
Gain on derivative warrant liabilities	2,191
Previously Reported
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Net loss	(2,881)
Revision of Prior Period, Error Correction, Adjustment
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Net loss	2,180
Gain on derivative warrant liabilities	$ 2,191

Significant Accounting Polici_7

Significant Accounting Policies - Previously Reported Financial Statements - Net Loss by Segment (Details) - USD ($) $ in Thousands	3 Months Ended
	Sep. 30, 2022	Sep. 30, 2021
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Net loss	$ (701)	$ (27,851)
Rx
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Net loss	126	(26,457)
Consumer Health
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Net loss	(827)	$ (1,394)
Previously Reported
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Net loss	(2,881)
Previously Reported \| Rx
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Net loss	(2,054)
Previously Reported \| Consumer Health
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Net loss	(827)
Revision of Prior Period, Error Correction, Adjustment
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Net loss	2,180
Revision of Prior Period, Error Correction, Adjustment \| Rx
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Net loss	$ 2,180

Significant Accounting Polici_8

Significant Accounting Policies - Warrants (Details)	Sep. 30, 2022	Aug. 09, 2022
Accounting Policies [Abstract]
Derivative Liability, Valuation Technique	us-gaap:ValuationTechniqueOptionPricingModelMember	us-gaap:ValuationTechniqueOptionPricingModelMember

Significant Accounting Polici_9

Significant Accounting Policies - Recent Adopted Accounting Pronouncements (Details)	Sep. 30, 2022
Accounting Standards Update 2020-04
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Change in Accounting Principle, Accounting Standards Update, Adopted	true
Change in Accounting Principle, Accounting Standards Update, Adoption Date	Jul. 01, 2022
Accounting Standards Update 2021-04
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Change in Accounting Principle, Accounting Standards Update, Adopted	true
Accounting Standards Update 2020-06
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Change in Accounting Principle, Accounting Standards Update, Adopted	false
Accounting Standards Update 2016-13
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Change in Accounting Principle, Accounting Standards Update, Adopted	false

Revenues from Contracts with _3

Revenues from Contracts with Customers - Contract Balances (Details) - USD ($) $ in Millions	Sep. 30, 2022	Jun. 30, 2022
Contract with Customer, Liability [Abstract]
Contract with customer, liability, current	$ 0.1	$ 0.4

Revenues from Contracts with _4

Revenues from Contracts with Customers - Revenues by Product Portfolio (Details) - USD ($) $ in Thousands	3 Months Ended
	Sep. 30, 2022	Sep. 30, 2021
Disaggregation of Revenue [Line Items]
Revenue from contract with customer	$ 27,655	$ 21,897
Attention Deficit Hyperactivity Disorder Portfolio
Disaggregation of Revenue [Line Items]
Revenue from contract with customer	11,585	9,327
Pediatric Portfolio
Disaggregation of Revenue [Line Items]
Revenue from contract with customer	6,558	3,798
Consumer Health Portfolio
Disaggregation of Revenue [Line Items]
Revenue from contract with customer	9,003	8,014
Other Product Portfolio
Disaggregation of Revenue [Line Items]
Revenue from contract with customer	$ 509	$ 758

Revenues from Contracts with _5

Revenues from Contracts with Customers - Revenues by Geographic Location (Details) - USD ($) $ in Thousands	3 Months Ended
	Sep. 30, 2022	Sep. 30, 2021
Disaggregation of Revenue [Line Items]
Revenue from contract with customer	$ 27,655	$ 21,897
UNITED STATES
Disaggregation of Revenue [Line Items]
Revenue from contract with customer	27,476	21,106
Non-US
Disaggregation of Revenue [Line Items]
Revenue from contract with customer	$ 179	$ 791

Inventories - General Informati

Inventories - General Information (Details) - USD ($) $ in Millions	3 Months Ended
	Sep. 30, 2022	Sep. 30, 2021
Production Related Impairments or Charges [Abstract]
Inventory write-down and impairment	$ 0.1	$ 0.2

Inventories - Tabular Disclosur

Inventories - Tabular Disclosure (Details) - USD ($) $ in Thousands	Sep. 30, 2022	Jun. 30, 2022
Inventory, Net [Abstract]
Raw materials	$ 2,113	$ 1,814
Work in process	2,374	1,838
Finished goods	8,384	7,197
Inventory, net	$ 12,871	$ 10,849

Property and Equipment - Tabula

Property and Equipment - Tabular Disclosure (Details) - USD ($) $ in Thousands	Sep. 30, 2022	Jun. 30, 2022
Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, after Accumulated Depreciation and Amortization [Abstract]
Property and equipment, gross	$ 5,408	$ 5,446
Less accumulated depreciation and amortization	(2,736)	(2,421)
Property and equipment, net	2,672	3,025
Manufacturing Equipment
Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, after Accumulated Depreciation and Amortization [Abstract]
Property and equipment, gross	2,449	2,487
Leasehold Improvements
Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, after Accumulated Depreciation and Amortization [Abstract]
Property and equipment, gross	999	999
Office Equipment, Furniture and Other
Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, after Accumulated Depreciation and Amortization [Abstract]
Property and equipment, gross	1,128	1,128
Lab Equipment
Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, after Accumulated Depreciation and Amortization [Abstract]
Property and equipment, gross	$ 832	$ 832

Property and Equipment - Deprec

Property and Equipment - Depreciation Expense (Details) - USD ($) $ in Millions	3 Months Ended
	Sep. 30, 2022	Sep. 30, 2021
Depreciation, Depletion and Amortization [Abstract]
Depreciation expense	$ 0.3	$ 0.4

Leases - Net Lease Cost (Detail

Leases - Net Lease Cost (Details) - USD ($) $ in Thousands	3 Months Ended
Leases - Net Lease Cost (Details) - USD ($) $ in Thousands	Sep. 30, 2022	Sep. 30, 2021
Lease, Cost [Abstract]
Operating lease cost	$ 222	$ 296
Short-term lease cost	160	39
Amortization of leased assets	18	18
Interest on lease liabilities	3	4
Total net lease cost	$ 403	$ 357

Leases - Supplemental Balance S

Leases - Supplemental Balance Sheet Information (Details) - USD ($) $ in Thousands	Sep. 30, 2022	Jun. 30, 2022
Assets and Liabilities, Lessee [Abstract]
Operating lease assets	$ 2,976	$ 3,271
Finance lease assets	$ 238	$ 256
Finance Lease, Right-of-Use Asset, Statement of Financial Position	Property and equipment, net	Property and equipment, net
Total leased assets	$ 3,214	$ 3,527
Current portion of operating lease liabilities	1,252	1,227
Finance leases, current	$ 92	$ 96
Finance Lease, Liability, Current, Statement of Financial Position	Current portion of debt	Current portion of debt
Operating lease liabilities, net of current portion	$ 1,768	$ 2,090
Finance leases, long-term	$ 62	$ 84
Finance Lease, Liability, Noncurrent, Statement of Financial Position	Debt, net of current portion	Debt, net of current portion
Total lease liabilities	$ 3,174	$ 3,497

Leases - Remaining Lease Term a

Leases - Remaining Lease Term and Weighted-average Discount Rate (Details)	Sep. 30, 2022	Jun. 30, 2022
Lessee Disclosure [Abstract]
Operating lease assets, weighted-average remaining lease term	2 years 4 months 20 days	2 years 7 months 17 days
Finance lease assets, weighted-average remaining lease term	1 year 5 months 23 days	1 year 8 months 23 days
Operating lease assets, weighted-average discount rate	7.54%	7.48%
Finance lease assets, weighted-average discount rate	6.43%	6.43%

Leases - Cash Flow Information

Leases - Cash Flow Information (Details) - USD ($) $ in Thousands	3 Months Ended
	Sep. 30, 2022	Sep. 30, 2021
Cash Flow, Operating Activities, Lessee [Abstract]
Operating cash flows from operating leases	$ 357	$ 282
Cash Flow, Investing Activities, Lessee [Abstract]
Operating cash flows from finance leases	3	4
Cash Flow, Financing Activities, Lessee [Abstract]
Financing cash flows from finance leases	$ 27	$ 25

Leases - Operating Leases - Fut

Leases - Operating Leases - Future Minimum Lease Payments (Details) $ in Thousands	Sep. 30, 2022 USD ($)
Lessee, Operating Lease, Liability, Payment, Due [Abstract]
2023 (remaining 9 months)	$ 1,079
2024	1,379
2025	749
2026	90
2027	46
Total lease payments	$ 3,343

Leases - Operating Leases - Gro

Leases - Operating Leases - Gross Difference (Details) - USD ($) $ in Thousands	Sep. 30, 2022	Jun. 30, 2022
Operating Lease Liabilities, Gross Difference, Amount [Abstract]
Total lease payments	$ 3,343
Less: Imputed interest	(323)
Lease liabilities	$ 3,020	$ 3,317

Leases - Finance Leases - Futur

Leases - Finance Leases - Future Minimum Lease Payments (Details) $ in Thousands	Sep. 30, 2022 USD ($)
Finance Lease, Liability, Payment, Due [Abstract]
2023 (remaining 9 months)	$ 75
2024	87
Total lease payments	$ 162

Leases - Finance Leases - Gross

Leases - Finance Leases - Gross Difference (Details) $ in Thousands	Sep. 30, 2022 USD ($)
Finance Lease Liabilities, Gross Difference, Amount [Abstract]
Total lease payments	$ 162
Less: Imputed interest	(8)
Lease liabilities	$ 154

Goodwill and Other Intangible_3

Goodwill and Other Intangible Assets - Intangible Assets Impairment (Excluding Goodwill) (Details) $ in Thousands	3 Months Ended
	Sep. 30, 2022 USD ($)
Asset Impairment Charges [Abstract]
Impairment of intangible assets, indefinite-lived (excluding goodwill)	$ 0
Impairment of intangible assets, finite-lived	$ 0

Goodwill and Other Intangible_4

Goodwill and Other Intangible Assets - Goodwill Impairment (Details) $ in Millions	3 Months Ended
	Sep. 30, 2021 USD ($)
Asset Impairment Charges [Abstract]
Goodwill impairment	$ 19.5

Goodwill and Other Intangible_5

Goodwill and Other Intangible Assets - Finite-lived Intangible Assets (Details) - USD ($) $ in Thousands	Sep. 30, 2022	Jun. 30, 2022	Sep. 30, 2021
Finite-Lived Intangible Assets, Net [Abstract]
Finite-lived intangible assets, gross carrying amount	$ 86,954	$ 91,620
Accumulated amortization	(15,050)	(16,530)
Impairment	(5,396)		$ (7,058)
Finite-lived intangible assets, net	66,508	68,032
Product Technology Right
Finite-Lived Intangible Assets, Net [Abstract]
Finite-lived intangible assets, gross carrying amount	45,400	45,400
Accumulated amortization	(8,471)	(7,667)
Impairment	(3,224)		(3,224)
Finite-lived intangible assets, net	33,705	34,509
Developed Technology Rights
Finite-Lived Intangible Assets, Net [Abstract]
Finite-lived intangible assets, gross carrying amount	30,200	30,200
Accumulated amortization	(2,722)	(2,278)
Finite-lived intangible assets, net	27,478	27,922
Product Distribution Rights
Finite-Lived Intangible Assets, Net [Abstract]
Finite-lived intangible assets, gross carrying amount	11,354	11,354
Accumulated amortization	(3,857)	(3,581)
Impairment	(2,172)		(2,172)
Finite-lived intangible assets, net	$ 5,325	5,601
Other Intangible Assets
Finite-Lived Intangible Assets, Net [Abstract]
Finite-lived intangible assets, gross carrying amount		4,666
Accumulated amortization		$ (3,004)
Impairment			$ (1,662)

Goodwill and Other Intangible_6

Goodwill and Other Intangible Assets - Weighted-average Remaining Life (Details) - Weighted Average	3 Months Ended	12 Months Ended
	Sep. 30, 2022	Jun. 30, 2022
Finite-Lived Intangible Assets [Line Items]
Finite-lived intangible assets, remaining amortization period	13 years 1 month 6 days	13 years 4 months 6 days
Product Technology Right
Finite-Lived Intangible Assets [Line Items]
Finite-lived intangible assets, remaining amortization period	12 years 14 days	12 years 3 months 29 days
Developed Technology Rights
Finite-Lived Intangible Assets [Line Items]
Finite-lived intangible assets, remaining amortization period	15 years 6 months	15 years 9 months
Product Distribution Rights
Finite-Lived Intangible Assets [Line Items]
Finite-lived intangible assets, remaining amortization period	7 years 4 months 6 days	7 years 7 months 6 days

Goodwill and Other Intangible_7

Goodwill and Other Intangible Assets - Intangible Assets (Details) - USD ($) $ in Thousands	Sep. 30, 2022	Jun. 30, 2022	Sep. 30, 2021
Intangible Assets, Net (Excluding Goodwill) [Abstract]
Finite-lived intangible assets, gross carrying amount	$ 86,954	$ 91,620
Indefinite-lived intangible assets	2,600	2,600
Intangible assets, gross carrying amount	89,554	94,220
Accumulated amortization	(15,050)	(16,530)
Impairment	(5,396)		$ (7,058)
Intangible assets, net carrying amount	$ 69,108	$ 70,632

Goodwill and Other Intangible_8

Goodwill and Other Intangible Assets - Estimated Future Amortization Expense (Details) - USD ($) $ in Thousands	Sep. 30, 2022	Jun. 30, 2022
Finite-Lived Intangible Assets, Net, Amortization Expense, Fiscal Year Maturity [Abstract]
2023 (remaining 9 months)	$ 4,563
2024	6,074
2025	5,934
2026	5,683
2027	5,652
2028	5,552
Thereafter	33,050
Finite-lived intangible assets, net	$ 66,508	$ 68,032

Goodwill and Other Intangible_9

Goodwill and Other Intangible Assets - Supply and Distribution Agreement (Details)	3 Months Ended
	Sep. 30, 2022
Supply and Distribution Agreement, Tris Pharma, Inc
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Supply and distribution agreement, term	20 years

Goodwill and Other Intangibl_10

Goodwill and Other Intangible Assets - Estimated Useful Life (Details)	3 Months Ended
	Sep. 30, 2022
Minimum
Finite-Lived Intangible Assets [Line Items]
Finite-lived intangible asset, useful life, renewable period	1 year
Maximum
Finite-Lived Intangible Assets [Line Items]
Finite-lived intangible asset, useful life, renewable period	20 years
Product Technology Right \| Attention Deficit Hyperactivity Disorder Portfolio
Finite-Lived Intangible Assets [Line Items]
Estimated useful lives	17 years

Goodwill and Other Intangibl_11

Goodwill and Other Intangible Assets - Product Distribution Rights and Customer List (Details) - Innovus Pharmaceuticals, Inc	1 Months Ended
	Feb. 29, 2020 product item
Business Acquisition [Line Items]
Number of products acquired \| product	35
Number of registered trademarks and or patent rights and customer lists acquired \| item	300

Goodwill and Other Intangibl_12

Goodwill and Other Intangible Assets - Amortization Expense (Details) - USD ($) $ in Millions	3 Months Ended
	Sep. 30, 2022	Sep. 30, 2021
Amortization [Abstract]
Amortization expense	$ 1.5	$ 2.1

Accrued Liabilities (Details)

Accrued Liabilities (Details) - USD ($) $ in Thousands	Sep. 30, 2022	Jun. 30, 2022
Accrued Liabilities, Current [Abstract]
Accrued savings offers	$ 11,801	$ 12,711
Accrued program liabilities	8,080	9,468
Product return reserve	5,826	5,770
Accrued employee compensation	5,679	4,765
Accrued customer and product related fees	6,832	7,817
Other accrued liabilities	3,213	3,656
Total accrued liabilities	$ 41,431	$ 44,187

Other Liabilities - Components

Other Liabilities - Components (Details) - USD ($) $ in Thousands	Sep. 30, 2022	Jun. 30, 2022
Other Liabilities, Unclassified [Abstract]
Fixed payment arrangements	$ 12,472	$ 13,051
Contingent value rights	706	578
Contingent consideration	423	396
Operating lease liabilities	3,020	3,317
Other	803	815
Total other liabilities	$ 17,424	$ 18,157

Other Liabilities - Classificat

Other Liabilities - Classification (Details) - USD ($) $ in Thousands	Sep. 30, 2022	Jun. 30, 2022
Other Liabilities [Abstract]
Total other liabilities	$ 17,424	$ 18,157
Less: current portion	(8,094)	(5,359)
Total other liabilities, noncurrent	$ 9,330	$ 12,798

Other Liabilities - Fixed Payme

Other Liabilities - Fixed Payment Arrangements (Details) $ in Thousands				1 Months Ended
	May 12, 2022 USD ($) payment	Jun. 21, 2021 USD ($)	May 29, 2020 USD ($)	Jan. 31, 2021 USD ($)	Jan. 31, 2020 USD ($)	Sep. 30, 2022 USD ($)	Jun. 30, 2022 USD ($)	Sep. 30, 2021 USD ($) payment	Nov. 01, 2019 USD ($) agreement
Other Commitments [Line Items]
Fixed payment arrangements						$ 12,472	$ 13,051
Fixed Payment Arrangements, Investor Assumed, Product Acquisition from Cerecor, Inc
Other Commitments [Line Items]
Fixed payment arrangements, periodic payment obligations, number \| agreement									2
Fixed Payment Arrangements, Investor Assumed, Product Acquisition from Cerecor, Inc, Periodic Payment Obligation, Fixed Payments
Other Commitments [Line Items]
Fixed payment arrangements, monthly payment amount									$ 100
Fixed payment arrangements, balloon payment amount									$ 15,000
Fixed payment arrangements, balloon payment amount, paid			$ 15,000
Fixed payment arrangements						1,000		$ 3,000
Fixed payment arrangements, quarterly payment amount, payments, number \| payment								6
Fixed payment arrangements, quarterly payment amount								$ 500
Fixed Payment Arrangements, Investor Assumed, Product Acquisition from Cerecor, Inc, Periodic Payment Obligation, Variable Payments
Other Commitments [Line Items]
Fixed payment arrangements, monthly variable payment amount, percentage of net revenue (as a percent)									15%
Fixed payment arrangements, monthly variable payment amount, minimum									$ 100
Fixed payment arrangements, monthly variable payment amount, one-time payment, paid				$ 200	$ 200
Fixed payment arrangements, monthly variable payment amount, aggregate payments to satisfy obligation if paid before 12 February 2026									9,300
Fixed payment arrangements, fixed, product minimum royalties per annum									$ 2,100
Fixed payment arrangements, payment amount, paid		$ 2,800
Fixed Payment Arrangements, Termination of Original License Agreement, Tris Pharma, Inc
Other Commitments [Line Items]
Fixed payment arrangements	$ 9,000					$ 6,900
Fixed payment arrangements, liability, reduction	$ 8,000
Fixed payment arrangements, installment payments, number \| payment	3
Fixed Payment Arrangements, TRIS Pharma, Inc, Royalty and Make Whole Payments
Other Commitments [Line Items]
Issues, fixed payment arrangements	$ 7,600

Other Liabilities - Supply and

Other Liabilities - Supply and Distribution Agreement (Details) - Supply and Distribution Agreement, Tris Pharma, Inc	3 Months Ended
	Sep. 30, 2022	Jun. 30, 2023 USD ($)	Sep. 30, 2022 USD ($)	Sep. 30, 2022 item
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Supply and distribution agreement, term	20 years
Supply and distribution agreement, royalty, percentage of net sales (as a percent)	23.50%
Supply and distribution agreement, minimum unit sales commitments, annual unit sales, units	70,000			70,000
Supply and distribution agreement, minimum unit sales commitments, royalty make whole payment under annual minimum sales commitment, per unit			$ 30
Supply and distribution agreement, minimum unit sales commitments, royalty make whole payment under annual minimum sales commitment, maximum annual amount			2,100,000
Supply and distribution agreement, commercial milestone obligations, cumulative net sales, maximum obligation			3,000,000
Supply and distribution agreement, commercial milestone obligations, net revenue trigger amount		$ 40,000,000	$ 40,000,000

Other Liabilities - Contingent

Other Liabilities - Contingent Value Rights (Details) - USD ($) $ in Thousands	3 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Jun. 30, 2022	Feb. 29, 2020
Other Liabilities Disclosure [Abstract]
Contingent value rights, business combination, contingent consideration, milestone payable, amount, maximum	$ 5,000			$ 16,000
Contingent value rights, business combination, contingent consideration, milestone payable, shares, maximum (in shares)				470,000
Contingent value rights	706		$ 578
Contingent value rights, gain (loss) for change in fair value during period	$ (100)	$ 100

Other Liabilities - Contingen_2

Other Liabilities - Contingent Consideration - Business Combination (Details) - Innovus Pharmaceuticals, Inc - USD ($) $ in Thousands	Sep. 30, 2022	Jun. 30, 2022	Feb. 29, 2020
Business Acquisition [Line Items]
Business combination, contingent consideration, license agreement, milestone payable, amount, every other year			$ 50
Business combination, contingent consideration, license agreement, milestone payable, amount			$ 200
Business combination, contingent consideration, license agreement, milestone payable, discount rate (as a percent)			26%
Business combination, contingent consideration, product related, milestone payable, amount			$ 200
Business combination, contingent consideration, product related, milestone payable, discount rate (as a percent)			30%
Contingent consideration	$ 400	$ 400

Other Liabilities - Contingen_3

Other Liabilities - Contingent Consideration - Other than Business Combination (Details) - USD ($) $ in Thousands	May 12, 2022	Mar. 31, 2021	Sep. 30, 2022	Jun. 30, 2022
Other Commitments [Line Items]
Other current liabilities			$ 8,094	$ 5,359
Licensing Agreements, TRIS Pharma, Inc, Royalty and Make Whole Payments
Other Commitments [Line Items]
Contingent consideration other than from business combination, liability, reversed in period	$ 8,500
Licensing Agreements, Magna Pharmaceuticals, Inc, ZolpiMist, Royalty Payments [Member]
Other Commitments [Line Items]
Contingent consideration other than from business combination, liability, reversed in period		$ 600
Other current liabilities		$ 50

Other Liabilities - Contingen_4

Other Liabilities - Contingent Consideration - Total (Details) - USD ($) $ in Millions	3 Months Ended
	Sep. 30, 2022	Sep. 30, 2021
Other Liabilities Disclosure [Abstract]
Business combination, contingent consideration, and contingent consideration other than from business combination, gain (loss) for change in fair value during period	$ 0	$ (0.2)
Business combination, contingent consideration, and contingent consideration other than from business combination, accretion expense	$ 0.1	$ 0.1

Line of Credit (Details)

Line of Credit (Details) - USD ($) $ in Millions	1 Months Ended	3 Months Ended
Line of Credit (Details) - USD ($) $ in Millions	Mar. 31, 2021	Sep. 30, 2022	Sep. 30, 2021	Jun. 30, 2022	Jan. 26, 2022	Jan. 25, 2022
Debt Instrument [Line Items]
Period of notice required before prepaying the debt instrument		5 days
Interest expense		$ 0.6	$ 0
Aggregate borrowing capacity					$ 3.5	$ 1
Amortization of deferred financing costs		$ 0.1
Revolving Credit Facility [Member]
Debt Instrument [Line Items]
Maximum borrowing capacity					$ 12.5	$ 25
Event Occurs on or before January 26, 2023 [Member]
Debt Instrument [Line Items]
Commitment fee percentage		2%
Event Occurs After January 26, 2023 But On or Before January 26, 2024 [Member]
Debt Instrument [Line Items]
Commitment fee percentage		1%
Event Occurs After January 26, 2024 But on or Before January 26, 2025 [Member]
Debt Instrument [Line Items]
Commitment fee percentage		0.50%
Neos Therapeutics, Inc [Member] \| Loan Agreement
Debt Instrument [Line Items]
Maximum borrowing capacity	$ 25
Maximum borrowing capacity portion available for short-term swingline loans	$ 2.5
Percentage of eligible accounts receivable against which short-term swingline loans may be made	85%
Unused capacity commitment fee percentage	0.50%
Outstanding amount		$ 8.1		$ 3.8
Neos Therapeutics, Inc [Member] \| Loan Agreement \| London Interbank Offered Rate (LIBOR)
Debt Instrument [Line Items]
Basis spread on variable rate	4.50%

Long-term Debt - Narrative (Det

Long-term Debt - Narrative (Details) - USD ($) $ in Thousands		3 Months Ended
	Jan. 26, 2022	Sep. 30, 2022	Sep. 30, 2021
Debt Instrument [Line Items]
Debt Instrument, Interest Payment Term	18 months
Debt Instrument, Interest Payment Extension Term	6 months
Interest Only Period Further Extension Term	12 months
Debt Instrument, Term of Trailing Months Revenue	12 months
Debt Instrument Prepayment Fee Percentage	3%
Long-term, final payment fee	$ 600	$ 638
Loan Processing Fee		$ 400
Debt Instrument, Interest Rate, Effective Percentage		15.37%
Interest expense		$ 600	$ 0
Event Occurs After January 26, 2023 But On or Before January 26, 2024 [Member]
Debt Instrument [Line Items]
Debt Instrument Prepayment Fee Percentage	2%
Event Occurs After January 26, 2024 But on or Before January 26, 2025 [Member]
Debt Instrument [Line Items]
Debt Instrument Prepayment Fee Percentage	1%
Avenue Capital Loan, Term Loan
Debt Instrument [Line Items]
Debt instrument, minimum variable rate before basis spread (as a percent)	3.25%
Debt instrument, basis spread on variable rate (as a percent)	7.40%
Face amount	$ 15,000

Long-term Debt - Warrants (Deta

Long-term Debt - Warrants (Details) - $ / shares	Mar. 07, 2022	Jan. 26, 2022
Class of Warrant or Right [Line Items]
Share price (in dollars per share)	$ 25
Warrants to Purchase Common Stock, Liability Classified, Avenue Capital Warrants, January 2022
Class of Warrant or Right [Line Items]
Class of warrant or right, date from which warrants or rights exercisable	Mar. 07, 2022	Jan. 26, 2022
Class of warrant or right, exercise price of warrants or rights (in dollars per share)	$ 24.20	$ 24.20
Class of warrant or right, number of securities called by warrants or right (in shares)	43,388

Long-term Debt - Composition (D

Long-term Debt - Composition (Details) - USD ($) $ in Thousands	Sep. 30, 2022	Jun. 30, 2022	Jan. 26, 2022
Debt Disclosure [Abstract]
Long-term debt, due on January 26, 2025	$ 15,000
Long-term, final payment fee	638		$ 600
Unamortized discount	(1,306)
Financing leases, maturing through May 2024	154
Total debt	14,485
Less current portion	(925)	$ (96)
Non-current portion of debt	$ 13,560	$ 14,279

Long-term Debt - Future Princip

Long-term Debt - Future Principal Payments (Details) - USD ($) $ in Thousands	Sep. 30, 2022	Jun. 30, 2022
Debt Disclosure [Abstract]
2023	$ 92
2024	8,395
2025	7,304
Future principal payments	15,791
Less unamortized discount and issuance costs	(1,306)
Less current portion	(925)	$ (96)
Non-current portion of debt	$ 13,560	$ 14,279

Fair Value Considerations - Rec

Fair Value Considerations - Recurring Basis (Details) - USD ($) $ in Thousands	Sep. 30, 2022	Jun. 30, 2022
Financial Liabilities Fair Value Disclosure [Abstract]
Contingent consideration	$ 423	$ 396
CVR liability	$ 706	$ 578
Derivative Liability, Statement of Financial Position	Derivative warrant liabilities	Derivative warrant liabilities
Fair Value, Recurring
Assets, Fair Value Disclosure [Abstract]
Cash and cash equivalents	$ 23,811	$ 19,360
Total	23,811	19,360
Financial Liabilities Fair Value Disclosure [Abstract]
Contingent consideration	423	396
CVR liability	706	578
Derivative warrant liabilities	5,558	1,796
Total	6,687	2,770
Fair Value, Recurring \| Fair Value, Inputs, Level 1
Assets, Fair Value Disclosure [Abstract]
Cash and cash equivalents	23,811	19,360
Total	23,811	19,360
Fair Value, Recurring \| Fair Value, Inputs, Level 3
Financial Liabilities Fair Value Disclosure [Abstract]
Contingent consideration	423	396
CVR liability	706	578
Derivative warrant liabilities	5,558	1,796
Total	$ 6,687	$ 2,770

Fair Value Considerations - Uno

Fair Value Considerations - Unobservable Inputs Reconciliation, Recurring Basis, Liabilities (Details) $ in Thousands	3 Months Ended
	Sep. 30, 2022 USD ($)
Contingent Value Rights
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Beginning balance	$ 578
Included in earnings	$ 128
Fair Value, Liability, Recurring Basis, Unobservable Input Reconciliation, Gain (Loss), Statement of Income or Comprehensive Income	Loss from contingent consideration
Ending balance	$ 706
Contingent Consideration
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Beginning balance	396
Included in earnings	$ 27
Fair Value, Liability, Recurring Basis, Unobservable Input Reconciliation, Gain (Loss), Statement of Income or Comprehensive Income	Loss from contingent consideration
Ending balance	$ 423
Derivative Financial Instruments, Liabilities
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Beginning balance	1,796
Included in earnings	$ (2,191)
Fair Value, Liability, Recurring Basis, Unobservable Input Reconciliation, Gain (Loss), Statement of Income or Comprehensive Income	Gain on derivative warrant liabilities
Issues	$ 5,953
Ending balance	$ 5,558

Fair Value Considerations - U_2

Fair Value Considerations - Unobservable Inputs Reconciliation, Non-recurring Basis, Liabilities (Details) $ in Thousands	3 Months Ended
	Sep. 30, 2022 USD ($)
Fair Value Disclosures [Abstract]
Beginning balance, fixed payment arrangements	$ 13,051
Included in earnings, fixed payment arrangements	446
Settlements, fixed payment arrangements	(1,025)
Ending balance, fixed payment arrangements	$ 12,472

Fair Value Considerations - Val

Fair Value Considerations - Valuation Assumptions (Details)	Sep. 30, 2022 Y	Aug. 09, 2022 Y
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Derivative Liability, Valuation Technique	us-gaap:ValuationTechniqueOptionPricingModelMember	us-gaap:ValuationTechniqueOptionPricingModelMember
Measurement Input, Leveraged Beta
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Contingent value rights, measurement input	0.84
Measurement Input, Market Risk Premium
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Contingent value rights, measurement input	0.0622
Measurement Input, Price Volatility
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Derivative liability, measurement input	0.8733	0.8989
Measurement Input, Expected Term
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Derivative liability, measurement input		4.11
Measurement Input, Expected Term \| Minimum
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Derivative liability, measurement input	4.11
Measurement Input, Expected Term \| Maximum
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Derivative liability, measurement input	4.94
Measurement Input, Risk Free Interest Rate
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Contingent value rights, measurement input	0.0409
Derivative liability, measurement input		0.0309
Measurement Input, Risk Free Interest Rate \| Minimum
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Derivative liability, measurement input	0.0406
Measurement Input, Risk Free Interest Rate \| Maximum
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Derivative liability, measurement input	0.0416
Measurement Input, Discount Rate
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Contingent value rights, measurement input	0.2150
Measurement Input, Discount for Lack of Marketability
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Contingent value rights, measurement input	0.1000
Measurement Input, Expected Dividend Rate
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Derivative liability, measurement input	0	0

Commitments and Contingencies -

Commitments and Contingencies - Fixed Payment Arrangements (Details) $ in Thousands				1 Months Ended
	May 12, 2022 USD ($)	Jun. 21, 2021 USD ($)	May 29, 2020 USD ($)	Jan. 31, 2021 USD ($)	Jan. 31, 2020 USD ($)	Sep. 30, 2022 USD ($)	Jun. 30, 2022 USD ($)	Sep. 30, 2021 USD ($) payment	Nov. 01, 2019 USD ($) agreement
Other Commitments [Line Items]
Fixed payment arrangements						$ 12,472	$ 13,051
Fixed Payment Arrangements, Investor Assumed, Product Acquisition from Cerecor, Inc
Other Commitments [Line Items]
Fixed payment arrangements, periodic payment obligations, number \| agreement									2
Fixed Payment Arrangements, Investor Assumed, Product Acquisition from Cerecor, Inc, Periodic Payment Obligation, Fixed Payments
Other Commitments [Line Items]
Fixed payment arrangements, monthly payment amount									$ 100
Fixed payment arrangements, balloon payment amount									15,000
Fixed payment arrangements, balloon payment amount, paid			$ 15,000
Fixed payment arrangements						1,000		$ 3,000
Fixed payment arrangements, quarterly payment amount, payments, number \| payment								6
Fixed payment arrangements, quarterly payment amount								$ 500
Fixed Payment Arrangements, Investor Assumed, Product Acquisition from Cerecor, Inc, Periodic Payment Obligation, Variable Payments
Other Commitments [Line Items]
Fixed payment arrangements, monthly variable payment amount, minimum									$ 100
Fixed payment arrangements, monthly variable payment amount, one-time payment, paid				$ 200	$ 200
Fixed payment arrangements, payment amount, paid		$ 2,800
Fixed Payment Arrangements, Termination of Original License Agreement, Tris Pharma, Inc
Other Commitments [Line Items]
Fixed payment arrangements	$ 9,000					$ 6,900
Fixed Payment Arrangements, TRIS Pharma, Inc, Royalty and Make Whole Payments
Other Commitments [Line Items]
Issues, fixed payment arrangements	$ 7,600

Commitments and Contingencies_2

Commitments and Contingencies - Supply and Distribution Agreement (Details) - Supply and Distribution Agreement, Tris Pharma, Inc	3 Months Ended
	Sep. 30, 2022	Jun. 30, 2023 USD ($)	Sep. 30, 2022 USD ($)	Sep. 30, 2022 item
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Supply and distribution agreement, term	20 years
Supply and distribution agreement, royalty, percentage of net sales (as a percent)	23.50%
Supply and distribution agreement, minimum unit sales commitments, annual unit sales, units	70,000			70,000
Supply and distribution agreement, minimum unit sales commitments, royalty make whole payment under annual minimum sales commitment, per unit			$ 30
Supply and distribution agreement, minimum unit sales commitments, royalty make whole payment under annual minimum sales commitment, maximum annual amount			2,100,000
Supply and distribution agreement, commercial milestone obligations, cumulative net sales, maximum obligation			3,000,000
Supply and distribution agreement, commercial milestone obligations, net revenue trigger amount		$ 40,000,000	$ 40,000,000

Commitments and Contingencies_3

Commitments and Contingencies - Product Contingent Liability (Details) $ in Thousands	Sep. 30, 2022 USD ($)	Jul. 01, 2021 USD ($)	Feb. 28, 2015 USD ($) payment
Product Contingent Liability, Novalere, FlutiCare
Other Commitments [Line Items]
Product contingent liability, additional payments, number, certain sales achieved \| payment			5
Product contingent liability, additional payments, amount, certain sales achieved			$ 500
Product Contingent Liability, UIRD
Other Commitments [Line Items]
Product contingent liability, milestone, payment, every other year		$ 50
Product contingent liability, milestone, payment		$ 200
Other commitment	$ 100

Commitments and Contingencies_4

Commitments and Contingencies - Earn Out Payments (Details) $ in Thousands	Apr. 12, 2021 USD ($)
Commercial Global License Agreements, AR101
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
License agreement, milestone, maximum earn-out, cash and common stock	$ 67,500
Commercial Global License Agreement, Denovo Biopharma LLC, AR101
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
License agreement, annual maintenance fee	25
License agreement, license option fee	600
License agreement, escalating royalties, maximum	101,700
Commercial Global License Agreement, Johns Hopkins University, AR101
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
License agreement, minimum annual royalties, low end of range	5
License agreement, minimum annual royalties, high end of range	$ 20
License agreement, royalties, percentage of net product sales (as a percent)	3%
License agreement, royalties, achievement of certain regulatory and commercial milestones, maximum	$ 1,600

Capital Structure - Common and

Capital Structure - Common and Preferred Stock (Details) - $ / shares	Sep. 30, 2022	Jun. 30, 2022
Common Stock, Number of Shares, Par Value and Other Disclosures [Abstract]
Common stock, shares authorized (in shares)	200,000,000	200,000,000
Common stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Common stock, shares issued (in shares)	3,121,471	1,928,941
Common stock, shares outstanding (in shares)	3,121,471	1,928,941
Preferred Stock, Number of Shares, Par Value and Other Disclosures [Abstract]
Preferred stock, shares authorized (in shares)	50,000,000	50,000,000
Preferred stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Preferred stock, shares issued (in shares)	0	0
Preferred stock, shares outstanding (in shares)	0	0

Capital Structure - Restricted

Capital Structure - Restricted Stock (Details) - shares	Sep. 30, 2022	Jun. 30, 2022
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock, shares outstanding (in shares)	3,121,471	1,928,941
Restricted Stock
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock, shares outstanding (in shares)	73,164

Capital Structure - Stock Offer

Capital Structure - Stock Offerings (Details) - USD ($) $ / shares in Units, $ in Thousands		3 Months Ended
	Aug. 11, 2022	Sep. 30, 2022	Sep. 30, 2021	Mar. 07, 2022	Sep. 28, 2021	Jun. 04, 2021	Jun. 08, 2020
Subsidiary, Sale of Stock [Line Items]
Share price (in dollars per share)				$ 25
Proceeds from issuance of common stock and warrants, net of issuance costs		$ 10,416	$ 307
Shelf Registration Statement, 2020 Shelf
Subsidiary, Sale of Stock [Line Items]
Shelf registration, amount authorized							$ 100,000
Shelf registration, remaining amount available for sale		43,000
Shelf Registration Statement, 2020 Shelf, At-the-market Sales Agreement
Subsidiary, Sale of Stock [Line Items]
At-the-market sales agreement, amount authorized						$ 30,000
At-the-market sales agreement, remaining amount available for sale		$ 11,800
Issuance of common stock (in shares)		31,407
Proceeds from issuance of stock		$ 400
Shelf Registration Statement, 2021 Shelf
Subsidiary, Sale of Stock [Line Items]
Shelf registration, amount authorized					$ 100,000
Shelf registration, remaining amount available for sale		$ 82,400
Shelf Registration Statement, 2021 Shelf, Underwritten Public Offering, August 2022
Subsidiary, Sale of Stock [Line Items]
Issuance of common stock (in shares)	1,075,290
Proceeds from issuance of common stock and warrants	$ 10,000
Underwriting discounts, commissions, and other offering expenses	900
Proceeds from issuance of common stock and warrants, net of issuance costs	$ 9,100

Capital Structure - Warrants (D

Capital Structure - Warrants (Details) - USD ($) $ / shares in Units, $ in Millions	Aug. 11, 2022	Mar. 07, 2022	Jan. 26, 2022	Aug. 31, 2022
Warrants to Purchase Common Stock, Liability Classified, Avenue Capital Warrants, January 2022
Class of Warrant or Right [Line Items]
Class of warrant or right, date from which warrants or rights exercisable		Mar. 07, 2022	Jan. 26, 2022
Class of warrant or right, number of securities called by warrants or right (in shares)		43,388
Class of warrant or right, exercise price of warrants or rights (in dollars per share)		$ 24.20	$ 24.20
Warrants to Purchase Common Stock, Liability Classified, August 2022
Class of Warrant or Right [Line Items]
Class of warrant or right, date from which warrants or rights exercisable	Aug. 11, 2022
Class of warrant or right, offering price (in dollars per share)	$ 8.58
Fair value of warrants	$ 6
Warrants to Purchase Common Stock, Liability Classified, Pre-funded Warrants, August 2022
Class of Warrant or Right [Line Items]
Class of warrant or right, number of securities called by warrants or right (in shares)	87,500
Class of warrant or right, number of securities called by each warrant or right (in shares)	1
Class of warrant or right, exercise price of warrants or rights (in dollars per share)	$ 0.001			$ 0.02
Warrants to Purchase Common Stock, Liability Classified, Common Warrants, August 2022
Class of Warrant or Right [Line Items]
Class of warrant or right, number of securities called by warrants or right (in shares)	1,265,547
Class of warrant or right, number of securities called by each warrant or right (in shares)	1
Class of warrant or right, exercise price of warrants or rights (in dollars per share)	$ 8.60
Warrants and rights outstanding, term	5 years

Equity Incentive Plans - Genera

Equity Incentive Plans - General Information (Details) - shares		3 Months Ended
	Apr. 19, 2021	Sep. 30, 2022	Jun. 30, 2022	Mar. 31, 2021	Feb. 13, 2020	Jun. 01, 2015
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of options outstanding (in shares)		3,799	3,899
Restricted Stock Units (RSUs)
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unvested units outstanding (in shares)		8,500	8,500
Aytu 2015 Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares authorized (in shares)					250,000	150,000
Number of shares available for grant (in shares)		120,876
Aytu 2015 Plan \| Share-Based Payment Arrangement, Option
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Term of award		10 years
Aytu 2015 Plan \| Share-Based Payment Arrangement, Option \| Minimum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period		3 years
Aytu 2015 Plan \| Share-Based Payment Arrangement, Option \| Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period		4 years
Aytu 2015 Plan \| Restricted Stock
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unvested units outstanding (in shares)		68,160	80,373
Aytu 2015 Plan \| Restricted Stock \| Minimum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period		4 years
Aytu 2015 Plan \| Restricted Stock \| Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period		10 years
Aytu 2015 Plan \| Restricted Stock Units (RSUs)
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period		4 years
Neos 2015 Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of options outstanding (in shares)				3,486
Registered shares of common stock (in shares)	62,766
Number of shares available for grant (in shares)	5,272	2,352
Neos 2015 Plan \| Share-Based Payment Arrangement, Option
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Term of award		10 years
Neos 2015 Plan \| Share-Based Payment Arrangement, Option \| Minimum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period		1 year
Neos 2015 Plan \| Share-Based Payment Arrangement, Option \| Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period		4 years
Neos 2015 Plan \| Restricted Stock Units (RSUs)
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unvested units outstanding (in shares)				1,786

Equity Incentive Plans - Stock

Equity Incentive Plans - Stock Options (Details) - $ / shares	3 Months Ended	12 Months Ended
	Sep. 30, 2022	Jun. 30, 2022
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]
Number of options outstanding, beginning balance (in shares)	3,899
Forfeited/cancelled (in shares)	(74)
Expired (in shares)	(26)
Number of options outstanding, ending balance (in shares)	3,799	3,899
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]
Weighted average exercise price outstanding, beginning balance (in dollars per share)	$ 209.70
Forfeited/cancelled (in dollars per share)	126.84
Expired (in dollars per share)	157.84
Weighted average exercise price outstanding, ending balance (in dollars per share)	$ 211.67	$ 209.70
Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]
Outstanding, weighted average remaining contractual life (Year)	7 years 5 months 8 days	7 years 9 months 7 days
Number of options exercisable	2,666
Weighted average exercise price exercisable (in dollars per share)	$ 231.99
Weighted average remaining contractual life in years exercisable	7 years 4 months 28 days

Equity Incentive Plans - Restri

Equity Incentive Plans - Restricted Stock - Activity (Details) - Restricted Stock - Aytu 2015 Plan	3 Months Ended
	Sep. 30, 2022 $ / shares shares
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]
Unvested outstanding, beginning balance (in shares) \| shares	80,373
Granted (in shares) \| shares	325
Vested (in shares) \| shares	(10,545)
Forfeited/Cancelled (in shares) \| shares	(1,993)
Unvested outstanding, ending balance (in shares) \| shares	68,160
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]
Unvested, weighted average grant date fair value outstanding, beginning balance (in dollars per share) \| $ / shares	$ 148.91
Granted (in dollars per share) \| $ / shares	13.40
Vested (in dollars per share) \| $ / shares	115.60
Forfeited/Cancelled (in dollars per share) \| $ / shares	149.48
Unvested, weighted average grant date fair value outstanding, ending balance (in dollars per share) \| $ / shares	$ 153.40

Equity Incentive Plans - Rest_2

Equity Incentive Plans - Restricted Stock - Additional Information (Details) - Restricted Stock - Non-plan - shares	Jan. 17, 2022	Sep. 30, 2022
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unvested units outstanding (in shares)		4
Management
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Granted (in shares)	5,000

Equity Incentive Plans - Rest_3

Equity Incentive Plans - Restricted Stock Units (Details) - Restricted Stock Units (RSUs)	3 Months Ended
	Sep. 30, 2022 $ / shares shares
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]
Unvested outstanding, beginning balance (in shares) \| shares	8,500
Granted (in shares) \| shares	0
Unvested outstanding, ending balance (in shares) \| shares	8,500
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]
Unvested, weighted average grant date fair value outstanding, beginning balance (in dollars per share) \| $ / shares	$ 25.88
Granted (in dollars per share) \| $ / shares	0
Unvested, weighted average grant date fair value outstanding, ending balance (in dollars per share) \| $ / shares	$ 25.88

Equity Incentive Plans - Unreco

Equity Incentive Plans - Unrecognized Compensation Costs (Details) $ in Millions	3 Months Ended
	Sep. 30, 2022 USD ($)
Unrecognized compensation costs
Unrecognized compensation costs, options	$ 0.1
Share-Based Payment Arrangement, Option
Unrecognized compensation costs
Unrecognized compensation costs, period for recognition	1 year 4 months 24 days
Restricted Stock \| Aytu 2015 Plan
Unrecognized compensation costs
Unrecognized compensation costs, excluding options	$ 8.2
Unrecognized compensation costs, period for recognition	2 years 6 months
Restricted Stock \| Non-plan
Unrecognized compensation costs
Unrecognized compensation costs, excluding options	$ 0.5
Unrecognized compensation costs, period for recognition	3 years 7 months 6 days
Restricted Stock Units (RSUs)
Unrecognized compensation costs
Unrecognized compensation costs, excluding options	$ 0.2
Unrecognized compensation costs, period for recognition	2 years 4 months 13 days

Equity Incentive Plans - Stock-

Equity Incentive Plans - Stock-based Compensation Expense (Details) - USD ($) $ in Thousands	3 Months Ended
	Sep. 30, 2022	Sep. 30, 2021
Stock-based compensation expense
Total share-based compensation expense	$ 1,177	$ 1,519
Cost of Sales
Stock-based compensation expense
Total share-based compensation expense	5	9
Research and Development Expense
Stock-based compensation expense
Total share-based compensation expense	9	319
Selling and Marketing Expense
Stock-based compensation expense
Total share-based compensation expense	3	9
General and Administrative Expense
Stock-based compensation expense
Total share-based compensation expense	$ 1,160	$ 1,182

Warrants - Stock Issued (Detail

Warrants - Stock Issued (Details)	Mar. 07, 2022 $ / shares shares
Subsidiary, Sale of Stock [Line Items]
Share price (in dollars per share) \| $ / shares	$ 25
Shelf Registration Statement, 2021 Shelf, Underwritten Public Offering, March 2022
Subsidiary, Sale of Stock [Line Items]
Issuance of common stock (in shares) \| shares	151,500

Warrants - General Information

Warrants - General Information (Details) $ / shares in Units, $ in Millions	Aug. 11, 2022 USD ($) D $ / shares shares	Mar. 07, 2022 USD ($) $ / shares shares	Jan. 26, 2022 $ / shares	Sep. 30, 2022 shares	Aug. 31, 2022 $ / shares	Jun. 30, 2022 shares
Warrants to Purchase Common Stock [Member]
Class of Warrant or Right [Line Items]
Outstanding warrants (in shares)				1,698,721		433,174
Warrants to Purchase Common Stock, Liability Classified, Avenue Capital Warrants, January 2022
Class of Warrant or Right [Line Items]
Class of warrant or right, number of securities called by warrants or right (in shares)		43,388
Class of warrant or right, exercise price of warrants or rights (in dollars per share) \| $ / shares		$ 24.20	$ 24.20
Class of warrant or right, date from which warrants or rights exercisable		Mar. 07, 2022	Jan. 26, 2022
Warrants to Purchase Common Stock, Liability Classified, March 2022
Class of Warrant or Right [Line Items]
Fair value of warrants \| $		$ 3.2
Warrants to Purchase Common Stock, Liability Classified, Pre-funded Warrants, March 2022
Class of Warrant or Right [Line Items]
Class of warrant or right, number of securities called by warrants or right (in shares)		151,500
Class of warrant or right, exercise price of warrants or rights (in dollars per share) \| $ / shares		$ 0.002
Warrants to Purchase Common Stock, Liability Classified, Common Warrants, March 2022
Class of Warrant or Right [Line Items]
Class of warrant or right, number of securities called by warrants or right (in shares)		333,300
Class of warrant or right, number of securities called by each warrant or right (in shares)		1.1
Class of warrant or right, exercise price of warrants or rights (in dollars per share) \| $ / shares		$ 26
Class of warrant or right, date from which warrants or rights exercisable		Sep. 07, 2022
Warrants and rights outstanding, term		5 years
Warrants to Purchase Common Stock, Liability Classified, August 2022
Class of Warrant or Right [Line Items]
Class of warrant or right, date from which warrants or rights exercisable	Aug. 11, 2022
Fair value of warrants \| $	$ 6
Warrants to Purchase Common Stock, Liability Classified, Pre-funded Warrants, August 2022
Class of Warrant or Right [Line Items]
Class of warrant or right, number of securities called by warrants or right (in shares)	87,500
Class of warrant or right, number of securities called by each warrant or right (in shares)	1
Class of warrant or right, exercise price of warrants or rights (in dollars per share) \| $ / shares	$ 0.001				$ 0.02
Warrants to Purchase Common Stock, Liability Classified, Common Warrants, August 2022
Class of Warrant or Right [Line Items]
Class of warrant or right, number of securities called by warrants or right (in shares)	1,265,547
Class of warrant or right, number of securities called by each warrant or right (in shares)	1
Class of warrant or right, exercise price of warrants or rights (in dollars per share) \| $ / shares	$ 8.60
Warrants and rights outstanding, term	5 years
Class of warrant or right, exercise price adjustment, quotient, divisor, common stock, volume-weighted average price, 20 consecutive trading day period preceding 16th trading day, lowest trading days (in days) \| D	5
Class of warrant or right, exercise price adjustment, quotient, divisor, common stock, volume-weighted average price, consecutive trading days preceding 16th trading day (in days) \| D	20
Class of warrant or right, exercise price adjustment, quotient, dividend, scenario one	5
Class of warrant or right, exercise price adjustment, quotient, dividend, scenario two (in dollars per share) \| $ / shares	$ 2.32
Class of warrant or right, exercise price adjustment, maximum shares (in shares)	2,325,581
Class of warrant or right, exercise price adjustment, equity offering, common stock price lower than warrant exercise price prior to 2nd anniversary of Stock Combination Event, adjusted exercise price (in dollars per share) \| $ / shares	$ 2.32

Warrants - Warrants Activity (D

Warrants - Warrants Activity (Details) - Warrants to Purchase Common Stock - $ / shares	3 Months Ended	12 Months Ended
	Sep. 30, 2022	Jun. 30, 2022
Class of Warrant or Right [Line Items]
Outstanding, number of warrants (in shares)	433,174
Warrants issued (in shares)	1,353,047
Warrants exercised (in shares)	(87,500)
Outstanding, number of warrants (in shares)	1,698,721	433,174
Outstanding, weighted average remaining contractual life	4 years 9 months 3 days	4 years 8 months 23 days
Warrants issued, weighted average remaining contractual life	5 years
Warrants exercised, weighted average remaining contractual life	5 years
Weighted Average
Class of Warrant or Right [Line Items]
Outstanding, exercise price (in dollars per share)	$ 92.30
Warrants issued (in dollars per share)	3.30
Warrants exercised (in dollars per share)	0.02
Outstanding, exercise price (in dollars per share)	$ 31	$ 92.30

Net Loss Per Common Share (Deta

Net Loss Per Common Share (Details) - shares	3 Months Ended
Net Loss Per Common Share (Details) - shares	Sep. 30, 2022	Sep. 30, 2021
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities	1,784,184	173,161
Warrants to Purchase Common Stock, Liability Classified
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities	1,642,235	1,205
Warrants to Purchase Common Stock, Equity Classified
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities	56,486	58,022
Share-Based Payment Arrangement, Option
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities	3,799	4,793
Restricted Stock
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities	73,164	105,283
Restricted Stock Units (RSUs)
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities	8,500	3,858

License Agreements (Details)

License Agreements (Details) - USD ($) $ in Millions	1 Months Ended
License Agreements (Details) - USD ($) $ in Millions	Apr. 30, 2020	Oct. 31, 2017	Feb. 29, 2016
Licensing Agreement, Cedars-Sinai Medical Center, Healight
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
License agreement, term, after the first bona fide commercial sale of such licensed product in a country	10 years
License agreement, initial license fee paid	$ 0.3
License agreement, patent prosecution fees paid	$ 0.1
Settlement Agreement and Associated License Agreement, 2014, Shire LLC, New Drug Application
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
License agreement, up-front, non-refundable license fee paid, maximum			$ 1
License Agreement, 2017, Shire LLC, New Drug Application
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
License agreement, up-front, non-refundable license fee paid, maximum		$ 1

Segment Reporting - General Inf

Segment Reporting - General Information (Details) - segment	3 Months Ended
Segment Reporting - General Information (Details) - segment	Sep. 30, 2022	Sep. 30, 2021
Segment Reporting, Disclosure of Entity's Reportable Segments [Abstract]
Number of reportable segments	2	2

Segment Reporting - Consolidate

Segment Reporting - Consolidated Revenue (Details) - USD ($) $ in Thousands	3 Months Ended
	Sep. 30, 2022	Sep. 30, 2021
Revenues [Abstract]
Revenue from contract with customer	$ 27,655	$ 21,897
Rx
Revenues [Abstract]
Revenue from contract with customer	18,652	13,883
Consumer Health
Revenues [Abstract]
Revenue from contract with customer	$ 9,003	$ 8,014

Segment Reporting - Consolida_2

Segment Reporting - Consolidated Net Income (Loss) (Details) - USD ($) $ in Thousands	3 Months Ended
	Sep. 30, 2022	Sep. 30, 2021
Segment Reporting Information, Profit (Loss) [Abstract]
Net loss	$ (701)	$ (27,851)
Rx
Segment Reporting Information, Profit (Loss) [Abstract]
Net loss	126	(26,457)
Consumer Health
Segment Reporting Information, Profit (Loss) [Abstract]
Net loss	$ (827)	$ (1,394)

Segment Reporting - Total Asset

Segment Reporting - Total Assets (Details) - USD ($) $ in Thousands	Sep. 30, 2022	Jun. 30, 2022
Assets [Abstract]
Assets	$ 150,000	$ 137,623
Rx
Assets [Abstract]
Assets	134,067	121,377
Consumer Health
Assets [Abstract]
Assets	$ 15,933	$ 16,246

Subsequent Events (Details)

Subsequent Events (Details) - Warrants to Purchase Common Stock, Liability Classified, Avenue Capital Warrants, January 2022 - $ / shares	Oct. 25, 2022	Mar. 07, 2022	Jan. 26, 2022
Subsequent Event [Line Items]
Class of warrant or right, exercise price of warrants or rights (in dollars per share)		$ 24.20	$ 24.20
Subsequent Event
Subsequent Event [Line Items]
Class of warrant or right, exercise price of warrants or rights (in dollars per share)	$ 8.60

Uncategorized Items - aytu-2022

Label	Element	Value
Stock Issued During Period, Value, New Issues	us-gaap_StockIssuedDuringPeriodValueNewIssues	$ 270,000
Stock Issued During Period, Value, New Issues	us-gaap_StockIssuedDuringPeriodValueNewIssues	3,564,000
Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture	us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation	1,519,000
Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture	us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation	1,177,000
Share-based Payment Arrangement, Decrease for Tax Withholding Obligation	us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation	$ 6,000